Search

Your search keyword '"Porwit, A."' showing total 1,904 results
Start Over Author "Porwit, A."
1,904 results on '"Porwit, A."'

51. CD163+macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression

Author

de Matos Rodrigues, Joana, Lokhande, Lavanya, Olsson, Lina M., Hassan, May, Johansson, Angelica, Janská, Anna, Kumar, Darshan, Schmidt, Lina, Nikkarinen, Anna, Hollander, Peter, Glimelius, Ingrid, Porwit, Anna, Gerdtsson, Anna Sandstrom, Jerkeman, Mats, and Ek, Sara

Abstract

•MCL and infiltrating T cells show enhanced MAPK in the presence of CD163+macrophages.•CD163+macrophages promote immune suppression in regions proximal to the tumor.

Published
2024
Full Text
View/download PDF

56. Multiparameter flow cytometry in the evaluation of myelodysplasia

Author

Anna Porwit, Marie C. Béné, Carolien Duetz, Sergio Matarraz, Uta Oelschlaegel, Theresia M. Westers, Orianne Wagner‐Ballon, Shahram Kordasti, Peter Valent, Frank Preijers, Canan Alhan, Frauke Bellos, Peter Bettelheim, Kate Burbury, Nicolas Chapuis, Eline Cremers, Matteo G. Della Porta, Alan Dunlop, Lisa Eidenschink‐Brodersen, Patricia Font, Michaela Fontenay, Willemijn Hobo, Robin Ireland, Ulrika Johansson, Michael R. Loken, Kiyoyuki Ogata, Alberto Orfao, Katherina Psarra, Leonie Saft, Dolores Subira, Jeroen te Marvelde, Denise A. Wells, Vincent H. J. van der Velden, Wolfgang Kern, and Arjan A. van de Loosdrecht

Subjects
All institutes and research themes of the Radboud University Medical Center, Histology, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], Cell Biology, Pathology and Forensic Medicine
Abstract

Contains fulltext : 290820.pdf (Publisher’s version ) (Open Access) Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow-up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic Syndromes (ELN iMDS Flow) on the analytical issues in MFC for the diagnostic work-up of MDS. Recommendations for the analysis of several BM cell subsets such as myeloid precursors, maturing granulocytic and monocytic components and erythropoiesis are given. A core set of 17 markers identified as independently related to a cytomorphologic diagnosis of myelodysplasia is suggested as mandatory for MFC evaluation of BM in a patient with cytopenia. A myeloid precursor cell (CD34(+) CD19(-) ) count >3% should be considered immunophenotypically indicative of myelodysplasia. However, MFC results should always be evaluated as part of an integrated hematopathology work-up. Looking forward, several machine-learning-based analytical tools of interest should be applied in parallel to conventional analytical methods to investigate their usefulness in integrated diagnostics, risk stratification, and potentially even in the evaluation of response to therapy, based on MFC data. In addition, compiling large uniform datasets is desirable, as most of the machine-learning-based methods tend to perform better with larger numbers of investigated samples, especially in such a heterogeneous disease as MDS. 01 januari 2023

Published
2023

57. MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53 – a Nordic Lymphoma Group study

Author

Rodrigues, Joana M., primary, Hollander, Peter, additional, Schmidt, Lina, additional, Gkika, Eirinaios, additional, Razmara, Masoud, additional, Kumar, Darshan, additional, Geisler, Christian, additional, Grønbæk, Kirsten, additional, Eskelund, Christian W., additional, Räty, Riikka, additional, Kolstad, Arne, additional, Sundström, Christer, additional, Glimelius, Ingrid, additional, Porwit, Anna, additional, Jerkeman, Mats, additional, and Ek, Sara, additional

Published
2023
Full Text
View/download PDF

58. SOLUBLE MACROPHAGE MARKER SCD163 PREDICTS OUTCOME IN BOTH CHEMOIMMUNOTHERAPY AND TARGETED THERAPY TREATED MANTLE CELL LYMPHOMA

Author

Nikkarinen, A., primary, Lokhande, L., additional, Amini, R., additional, Jerkeman, M., additional, Porwit, A., additional, Molin, D., additional, Enblad, G., additional, Kolstad, A., additional, Räty, R., additional, Hutchings, M., additional, Weibull, C. E., additional, Hollander, P., additional, Ek, S., additional, and Glimelius, I., additional

Published
2023
Full Text
View/download PDF

62. The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study

Author

Gudbjörg Jonsdottir, Sigrún H. Lund, Magnus Björkholm, Ingemar Turesson, Malin Hultcrantz, Anna Porwit, Yogesh S. Jethava, Ola Landgren, and Sigurdur Y. Kristinsson

Subjects
Specialties of internal medicine, RC581-951
Abstract

Abstract: In the present study, we aimed to evaluate 2 hypotheses. First, we hypothesize that prior malignancy is a proxy for genetic susceptibility that could be a risk factor for subsequent malignancy development in multiple myeloma (MM) patients. Second, we hypothesize that survival after MM is influenced by a prior malignancy. All patients diagnosed with MM from 1 January 1973 to 31 December 2010 were identified from the Swedish Cancer Register. Cox regression model was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) where prior malignancy was compared in MM patients who developed a subsequent malignancy and MM patients who did not. In another Cox regression model, survival was compared in MM patients with and without a prior malignancy diagnosis. A total of 19 791 patients were diagnosed with MM. Patients with a prior malignancy diagnosis had a significantly increased risk of developing a subsequent malignancy compared with MM patients without (HR 1.42, 95% CI 1.23-1.65, P < .001). MM patients with a prior malignancy diagnosis had a significant 1.21-fold increased risk of death (95% CI 1.115-1.26, P < .001) compared with MM patients without. MM patients with 2 or more prior malignancy diagnoses had a 1.34-fold increased risk of death (95% CI 1.19-1.52, P < .001). In this large population-based study, we report that prior malignancy increases the risk of subsequent malignancy development in MM patients. Furthermore, we found that prior malignancy negatively impacts survival and that >1 prior malignancy reduces survival even further.

Published
2017
Full Text
View/download PDF

63. EAHP 2020 workshop proceedings, pediatric myeloid neoplasms

Author

R. J. Leguit, A. Orazi, N. Kucine, H. M. Kvasnicka, U. Gianelli, D. A. Arber, A. Porwit, and M. Ponzoni

Subjects
Cell Biology, General Medicine, Molecular Biology, Pathology and Forensic Medicine
Abstract

The first section of the bone marrow workshop of the European Association of Haematopathology (EAHP) 2020 Virtual Meeting was dedicated to pediatric myeloid neoplasms. The section covered the whole spectrum of myeloid neoplasms, including myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), and acute myeloid leukemia (AML). The workshop cases are hereby presented, preceded by an introduction on these overall rare diseases in this age group. Very rare entities such as primary myelofibrosis, pediatric MDS with fibrosis, and MDS/MPN with JMML-like features and t(4;17)(q12;q21); FIP1L1::RARA fusion, are described in more detail.

Published
2022

67. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet

Author

van der Velden, VHJ, Preijers, F, Johansson, U, Westers, TM, Dunlop, A, Porwit, A, Bene, MC, Valent, P, te Marvelde, J, Wagner-Ballon, O, Oelschlaegel, U, Saft, L, Kordasti, S, Ireland, R, Cremers, E, Alhan, C, Duetz, C, Hobo, W, Chapuis, N, Fontenay, M, Bettelheim, P, Eidenshink-Brodersen, L, Font, P, Loken, MR, Matarraz, S, Ogata, K, Orfao, A, Psarra, K, Subira, D, Wells, DA, Della Porta, MG, Burbury, K, Bellos, F, Weiss, E, Kern, W, van de Loosdrecht, A, van der Velden, VHJ, Preijers, F, Johansson, U, Westers, TM, Dunlop, A, Porwit, A, Bene, MC, Valent, P, te Marvelde, J, Wagner-Ballon, O, Oelschlaegel, U, Saft, L, Kordasti, S, Ireland, R, Cremers, E, Alhan, C, Duetz, C, Hobo, W, Chapuis, N, Fontenay, M, Bettelheim, P, Eidenshink-Brodersen, L, Font, P, Loken, MR, Matarraz, S, Ogata, K, Orfao, A, Psarra, K, Subira, D, Wells, DA, Della Porta, MG, Burbury, K, Bellos, F, Weiss, E, Kern, W, and van de Loosdrecht, A

Abstract

BACKGROUND: Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. METHODS: Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. RESULTS: We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. CONCLUSIONS: These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.

Published
2023

68. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Author

Loosdrecht, AA, Kern, W, Porwit, A, Valent, P, Kordasti, S, Cremers, E, Alhan, C, Duetz, C, Dunlop, A, Hobo, W, Preijers, F, Wagner-Ballon, O, Chapuis, N, Fontenay, M, Bettelheim, P, Eidenschink-Brodersen, L, Font, P, Johansson, U, Loken, MR, Marvelde, JG, Matarraz, S, Ogata, K, Oelschlaegel, U, Orfao, A, Psarra, K, Subira, D, Wells, DA, Bene, MC, Della Porta, MG, Burbury, K, Bellos, F, van der Velden, VHJ, Westers, TM, Saft, L, Ireland, R, Loosdrecht, AA, Kern, W, Porwit, A, Valent, P, Kordasti, S, Cremers, E, Alhan, C, Duetz, C, Dunlop, A, Hobo, W, Preijers, F, Wagner-Ballon, O, Chapuis, N, Fontenay, M, Bettelheim, P, Eidenschink-Brodersen, L, Font, P, Johansson, U, Loken, MR, Marvelde, JG, Matarraz, S, Ogata, K, Oelschlaegel, U, Orfao, A, Psarra, K, Subira, D, Wells, DA, Bene, MC, Della Porta, MG, Burbury, K, Bellos, F, van der Velden, VHJ, Westers, TM, Saft, L, and Ireland, R

Abstract

This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

Published
2023

69. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group.

Author

Loosdrecht, A.A. van de, Kern, W., Porwit, A., Valent, P., Kordasti, S., Cremers, E., Alhan, C., Duetz, C., Dunlop, A., Hobo, W.A., Preijers, F.W., Wagner-Ballon, O., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenschink-Brodersen, L., Font, P., Johansson, U., Loken, M.R., Marvelde, J.G. Te, Matarraz, S., Ogata, K., Oelschlaegel, U., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Béné, M.C., Porta, M.G. Della, Burbury, K., Bellos, F., Velden, V.H. van der, Westers, Theresia M., Saft, L., Ireland, R., Loosdrecht, A.A. van de, Kern, W., Porwit, A., Valent, P., Kordasti, S., Cremers, E., Alhan, C., Duetz, C., Dunlop, A., Hobo, W.A., Preijers, F.W., Wagner-Ballon, O., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenschink-Brodersen, L., Font, P., Johansson, U., Loken, M.R., Marvelde, J.G. Te, Matarraz, S., Ogata, K., Oelschlaegel, U., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Béné, M.C., Porta, M.G. Della, Burbury, K., Bellos, F., Velden, V.H. van der, Westers, Theresia M., Saft, L., and Ireland, R.

Abstract

01 januari 2023, Item does not contain fulltext, This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

Published
2023

70. Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group.

Author

Kern, W., Westers, Theresia M., Bellos, F., Bene, M.C., Bettelheim, P., Brodersen, L.E., Burbury, K., Chu, S.C., Cullen, M., Porta, M.D., Dunlop, A.S., Johansson, U., Matarraz, S., Oelschlaegel, U., Ogata, K., Porwit, A., Preijers, F.W., Psarra, K., Saft, L., Subirá, D., Weiß, E., Velden, V.H. van der, Loosdrecht, A. van de, Kern, W., Westers, Theresia M., Bellos, F., Bene, M.C., Bettelheim, P., Brodersen, L.E., Burbury, K., Chu, S.C., Cullen, M., Porta, M.D., Dunlop, A.S., Johansson, U., Matarraz, S., Oelschlaegel, U., Ogata, K., Porwit, A., Preijers, F.W., Psarra, K., Saft, L., Subirá, D., Weiß, E., Velden, V.H. van der, and Loosdrecht, A. van de

Abstract

01 januari 2023, Item does not contain fulltext, BACKGROUND: Myelodysplastic syndromes (MDS) represent a diagnostic challenge. This prospective multicenter study was conducted to evaluate pre-defined flow cytometric markers in the diagnostic work-up of MDS and chronic myelomonocytic leukemia (CMML). METHODS: Thousand six hundred and eighty-two patients with suspected MDS/CMML were analyzed by both cytomorphology according to WHO 2016 criteria and flow cytometry according to ELN recommendations. Flow cytometric readout was categorized 'non-MDS' (i.e. no signs of MDS/CMML and limited signs of MDS/CMML) and 'in agreement with MDS' (i.e., in agreement with MDS/CMML). RESULTS: Flow cytometric readout categorized 60% of patients in agreement with MDS, 28% showed limited signs of MDS and 12% had no signs of MDS. In 81% of cases flow cytometric readouts and cytomorphologic diagnosis correlated. For high-risk MDS, the level of concordance was 92%. A total of 17 immunophenotypic aberrancies were found independently related to MDS/CMML in ≥1 of the subgroups of low-risk MDS, high-risk MDS, CMML. A cut-off of ≥3 of these aberrancies resulted in 80% agreement with cytomorphology (20% cases concordantly negative, 60% positive). Moreover, >3% myeloid progenitor cells were significantly associated with MDS (286/293 such cases, 98%). CONCLUSION: Data from this prospective multicenter study led to recognition of 17 immunophenotypic markers allowing to identify cases 'in agreement with MDS'. Moreover, data emphasizes the clinical utility of immunophenotyping in MDS diagnostics, given the high concordance between cytomorphology and the flow cytometric readout. Results from the current study challenge the application of the cytomorphologically defined cut-off of 5% blasts for flow cytometry and rather suggest a 3% cut-off for the latter.

Published
2023

71. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet.

Author

Velden, V.H. van der, Preijers, F.W., Johansson, U., Westers, Theresia M., Dunlop, A., Porwit, A., Béné, M.C., Valent, P., Marvelde, J. Te, Wagner-Ballon, O., Oelschlaegel, U., Saft, L., Kordasti, S., Ireland, R., Cremers, E., Alhan, C., Duetz, C., Hobo, W.A., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenshink-Brodersen, L., Font, P., Loken, M.R., Matarraz, S., Ogata, K., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Porta, M.G. Della, Burbury, K., Bellos, F., Weiß, E., Kern, W., Loosdrecht, A. van de, Velden, V.H. van der, Preijers, F.W., Johansson, U., Westers, Theresia M., Dunlop, A., Porwit, A., Béné, M.C., Valent, P., Marvelde, J. Te, Wagner-Ballon, O., Oelschlaegel, U., Saft, L., Kordasti, S., Ireland, R., Cremers, E., Alhan, C., Duetz, C., Hobo, W.A., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenshink-Brodersen, L., Font, P., Loken, M.R., Matarraz, S., Ogata, K., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Porta, M.G. Della, Burbury, K., Bellos, F., Weiß, E., Kern, W., and Loosdrecht, A. van de

Abstract

01 januari 2023, Item does not contain fulltext, BACKGROUND: Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. METHODS: Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. RESULTS: We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. CONCLUSIONS: These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.

Published
2023

72. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group.

Author

Porwit, A., Béné, M.C., Duetz, C., Matarraz, S., Oelschlaegel, U., Westers, Theresia M., Wagner-Ballon, O., Kordasti, S., Valent, P., Preijers, F.W., Alhan, C., Bellos, F., Bettelheim, P., Burbury, K., Chapuis, N., Cremers, E., Porta, M.G. Della, Dunlop, A., Eidenschink-Brodersen, L., Font, P., Fontenay, M., Hobo, W., Ireland, R., Johansson, U., Loken, M.R., Ogata, K., Orfao, A., Psarra, K., Saft, L., Subira, D., Marvelde, J. Te, Wells, D.A., Velden, V.H. van der, Kern, W., Loosdrecht, A.A. van de, Porwit, A., Béné, M.C., Duetz, C., Matarraz, S., Oelschlaegel, U., Westers, Theresia M., Wagner-Ballon, O., Kordasti, S., Valent, P., Preijers, F.W., Alhan, C., Bellos, F., Bettelheim, P., Burbury, K., Chapuis, N., Cremers, E., Porta, M.G. Della, Dunlop, A., Eidenschink-Brodersen, L., Font, P., Fontenay, M., Hobo, W., Ireland, R., Johansson, U., Loken, M.R., Ogata, K., Orfao, A., Psarra, K., Saft, L., Subira, D., Marvelde, J. Te, Wells, D.A., Velden, V.H. van der, Kern, W., and Loosdrecht, A.A. van de

Abstract

01 januari 2023, Item does not contain fulltext, Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow-up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic Syndromes (ELN iMDS Flow) on the analytical issues in MFC for the diagnostic work-up of MDS. Recommendations for the analysis of several BM cell subsets such as myeloid precursors, maturing granulocytic and monocytic components and erythropoiesis are given. A core set of 17 markers identified as independently related to a cytomorphologic diagnosis of myelodysplasia is suggested as mandatory for MFC evaluation of BM in a patient with cytopenia. A myeloid precursor cell (CD34(+) CD19(-) ) count >3% should be considered immunophenotypically indicative of myelodysplasia. However, MFC results should always be evaluated as part of an integrated hematopathology work-up. Looking forward, several machine-learning-based analytical tools of interest should be applied in parallel to conventional analytical methods to investigate their usefulness in integrated diagnostics, risk stratification, and potentially even in the evaluation of response to therapy, based on MFC data. In addition, compiling large uniform datasets is desirable, as most of the machine-learning-based methods tend to perform better with larger numbers of investigated samples, especially in such a heterogeneous disease as MDS.

Published
2023

73. Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established high-risk factors

Author

Gerdtsson, Anna Sandström, de Matos Rodrigues, Joana, Eskelund, Christian Winther, Husby, Simon, Grønbæk, Kirsten, Räty, Riikka, Kolstad, Arne, Geisler, Christian, Porwit, Anna, Jerkeman, Mats, Ek, Sara, Gerdtsson, Anna Sandström, de Matos Rodrigues, Joana, Eskelund, Christian Winther, Husby, Simon, Grønbæk, Kirsten, Räty, Riikka, Kolstad, Arne, Geisler, Christian, Porwit, Anna, Jerkeman, Mats, and Ek, Sara

Abstract

The variable outcome to standard immunochemotherapy for mantle cell lymphoma (MCL) patients is a clinical challenge. Established risk factors, including high MCL International Prognostic Index (MIPI), high proliferation (Ki-67), non-classic (blastoid/pleomorphic) morphology, and mutated TP53, only partly identify patients in need of alternative treatment. Deepened understanding of biological factors that influence time to progression and relapse would allow for an improved stratification, and identification of novel targets for high-risk patients. We performed gene expression analyses to identify pathways and genes associated with outcome in a cohort of homogeneously treated patients. In addition to deregulated proliferation, we show that thermogenesis, fatty acid degradation and oxidative phosphorylation are altered in patients with poor survival, and that high expression of carnitine palmitoyltransferase 1A (CPT1A), an enzyme involved in fatty acid degradation, can specifically identify high-risk patients independent of the established high-risk factors. We suggest that complementary investigations of metabolism may increase the accuracy of patient stratification and that immunohistochemistry-based assessment of CPT1A can contribute to defining high-risk MCL.

Published
2023

74. Multiparameter flow cytometry in the evaluation of myelodysplasia:Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group

Author

Porwit, Anna, Béné, Marie C., Duetz, Carolien, Matarraz, Sergio, Oelschlaegel, Uta, Westers, Theresia M., Wagner-Ballon, Orianne, Kordasti, Shahram, Valent, Peter, Preijers, Frank, Alhan, Canan, Bellos, Frauke, Bettelheim, Peter, Burbury, Kate, Chapuis, Nicolas, Cremers, Eline, Della Porta, Matteo G., Dunlop, Alan, Eidenschink-Brodersen, Lisa, Font, Patricia, Fontenay, Michaela, Hobo, Willemijn, Ireland, Robin, Johansson, Ulrika, Loken, Michael R., Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Saft, Leonie, Subira, Dolores, te Marvelde, Jeroen, Wells, Denise A., van der Velden, Vincent H.J., Kern, Wolfgang, van de Loosdrecht, Arjan A., Porwit, Anna, Béné, Marie C., Duetz, Carolien, Matarraz, Sergio, Oelschlaegel, Uta, Westers, Theresia M., Wagner-Ballon, Orianne, Kordasti, Shahram, Valent, Peter, Preijers, Frank, Alhan, Canan, Bellos, Frauke, Bettelheim, Peter, Burbury, Kate, Chapuis, Nicolas, Cremers, Eline, Della Porta, Matteo G., Dunlop, Alan, Eidenschink-Brodersen, Lisa, Font, Patricia, Fontenay, Michaela, Hobo, Willemijn, Ireland, Robin, Johansson, Ulrika, Loken, Michael R., Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Saft, Leonie, Subira, Dolores, te Marvelde, Jeroen, Wells, Denise A., van der Velden, Vincent H.J., Kern, Wolfgang, and van de Loosdrecht, Arjan A.

Abstract

Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow-up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic Syndromes (ELN iMDS Flow) on the analytical issues in MFC for the diagnostic work-up of MDS. Recommendations for the analysis of several BM cell subsets such as myeloid precursors, maturing granulocytic and monocytic components and erythropoiesis are given. A core set of 17 markers identified as independently related to a cytomorphologic diagnosis of myelodysplasia is suggested as mandatory for MFC evaluation of BM in a patient with cytopenia. A myeloid precursor cell (CD34+CD19−) count >3% should be considered immunophenotypically indicative of myelodysplasia. However, MFC results should always be evaluated as part of an integrated hematopathology work-up. Looking forward, several machine-learning-based analytical tools of interest should be applied in parallel to conventional analytical methods to investigate their usefulness in integrated diagnostics, risk stratification, and potentially even in the evaluation of response to therapy, based on MFC data. In addition, compiling large uniform datasets is desirable, as most of the machine-learning-based methods tend to perform better with larger numbers of investigated samples, especially in such a heterogeneous disease as MDS.

Published
2023

75. A series of case studies illustrating the role of flow cytometry in the diagnostic work-up of myelodysplastic syndromes

Author

Westers, Theresia M., Saft, Leonie, van der Velden, Vincent H. J., te Marvelde, Jeroen G., Dunlop, Alan, Ireland, Robin, Valent, Peter, Porwit, Anna, Bene, Marie C., van de Loosdrecht, Arjan A., Westers, Theresia M., Saft, Leonie, van der Velden, Vincent H. J., te Marvelde, Jeroen G., Dunlop, Alan, Ireland, Robin, Valent, Peter, Porwit, Anna, Bene, Marie C., and van de Loosdrecht, Arjan A.

Abstract

Current guidelines recommend flow cytometric analysis as part of the diagnostic assessment of patients with cytopenia suspected for myelodysplastic syndrome. Herein we describe the complete work-up of six cases using multimodal integrated diagnostics. Flow cytometry assessments are illustrated by plots from conventional and more recent analysis tools. The cases demonstrate the added value of flow cytometry in case of hypocellular, poor quality, or ambiguous bone marrow cytomorphology. Moreover, they demonstrate how immunophenotyping results support clinical decision-making in inconclusive and clinically 'difficult' cases.

Published
2023

76. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group

Author

Porwit, Anna, Béne, Marie C., Duetz, Carolien, Matarraz, Sergio, Oelschlaegel, Uta, Westers, Theresia M., Wagner-Ballon, Orianne, Kordasti, Sharham, Valent, Peter, Preijers, Frank W. M. B., Alhan, Canan, Bellos, Frauke, Bettelheim, Peter, Burbury, Kate, Chapuis, Nicolas, Cremers, Eline M. P., Della Porta, Matteo G., Dunlop, Alan, Eidenschink Brodersen, Lisa, Font, Patricia, Fontenay, Michaela, Hobo, Willemijn, Ireland, Robin, Johansson, Ulrika, Loken, Michael R., Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Saft, Leonie, Subirá, Dolores, Marvelde, Jeroen G. te, Wells, Denise A., Velden, Vincent H. J. van der, Kern, Wolfgang, Loosdrecht, Arjan A. Van De, Porwit, Anna, Béne, Marie C., Duetz, Carolien, Matarraz, Sergio, Oelschlaegel, Uta, Westers, Theresia M., Wagner-Ballon, Orianne, Kordasti, Sharham, Valent, Peter, Preijers, Frank W. M. B., Alhan, Canan, Bellos, Frauke, Bettelheim, Peter, Burbury, Kate, Chapuis, Nicolas, Cremers, Eline M. P., Della Porta, Matteo G., Dunlop, Alan, Eidenschink Brodersen, Lisa, Font, Patricia, Fontenay, Michaela, Hobo, Willemijn, Ireland, Robin, Johansson, Ulrika, Loken, Michael R., Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Saft, Leonie, Subirá, Dolores, Marvelde, Jeroen G. te, Wells, Denise A., Velden, Vincent H. J. van der, Kern, Wolfgang, and Loosdrecht, Arjan A. Van De

Abstract

Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow-up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic Syndromes (ELN iMDS Flow) on the analytical issues in MFC for the diagnostic work-up of MDS. Recommendations for the analysis of several BM cell subsets such as myeloid precursors, maturing granulocytic and monocytic components and erythropoiesis are given. A core set of 17 markers identified as independently related to a cytomorphologic diagnosis of myelodysplasia is suggested as mandatory for MFC evaluation of BM in a patient with cytopenia. A myeloid precursor cell (CD34+CD19−) count >3% should be considered immunophenotypically indicative of myelodysplasia. However, MFC results should always be evaluated as part of an integrated hematopathology work-up. Looking forward, several machine-learning-based analytical tools of interest should be applied in parallel to conventional analytical methods to investigate their usefulness in integrated diagnostics, risk stratification, and potentially even in the evaluation of response to therapy, based on MFC data. In addition, compiling large uniform datasets is desirable, as most of the machine-learning-based methods tend to perform better with larger numbers of investigated samples, especially in such a heterogeneous disease as MDS.

Published
2023

77. Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group

Author

Kern, Wolfgang, Westers, Theresia M., Bellos, Frauke, Bene, Marie Christine, Bettelheim, Peter, Eidenschink Brodersen, Lisa, Burbury, Kate, Chu, Sung-Chao, Cullen, Matthew, Della Porta, Matteo G., Dunlop, Alan, Johansson, Ulrika, Matarraz, Sergio, Oelschlaegel, Uta, Ogata, Kiyoyuki, Porwit, Anna, Preijers, Frank W. M. B., Psarra, Katherina, Saft, Leonie, Subirá, Dolores, Weiß, Elisabeth, Velden, Vincent H. J. van der, Loosdrecht, Arjan A. Van De, Kern, Wolfgang, Westers, Theresia M., Bellos, Frauke, Bene, Marie Christine, Bettelheim, Peter, Eidenschink Brodersen, Lisa, Burbury, Kate, Chu, Sung-Chao, Cullen, Matthew, Della Porta, Matteo G., Dunlop, Alan, Johansson, Ulrika, Matarraz, Sergio, Oelschlaegel, Uta, Ogata, Kiyoyuki, Porwit, Anna, Preijers, Frank W. M. B., Psarra, Katherina, Saft, Leonie, Subirá, Dolores, Weiß, Elisabeth, Velden, Vincent H. J. van der, and Loosdrecht, Arjan A. Van De

Abstract

[Background]: Myelodysplastic syndromes (MDS) represent a diagnostic challenge. This prospective multicenter study was conducted to evaluate pre-defined flow cytometric markers in the diagnostic work-up of MDS and chronic myelomonocytic leukemia (CMML). [Methods]: Thousand six hundred and eighty-two patients with suspected MDS/CMML were analyzed by both cytomorphology according to WHO 2016 criteria and flow cytometry according to ELN recommendations. Flow cytometric readout was categorized ‘non-MDS’ (i.e. no signs of MDS/CMML and limited signs of MDS/CMML) and ‘in agreement with MDS’ (i.e., in agreement with MDS/CMML). [Results]: Flow cytometric readout categorized 60% of patients in agreement with MDS, 28% showed limited signs of MDS and 12% had no signs of MDS. In 81% of cases flow cytometric readouts and cytomorphologic diagnosis correlated. For high-risk MDS, the level of concordance was 92%. A total of 17 immunophenotypic aberrancies were found independently related to MDS/CMML in ≥1 of the subgroups of low-risk MDS, high-risk MDS, CMML. A cut-off of ≥3 of these aberrancies resulted in 80% agreement with cytomorphology (20% cases concordantly negative, 60% positive). Moreover, >3% myeloid progenitor cells were significantly associated with MDS (286/293 such cases, 98%). [Conclusion]: Data from this prospective multicenter study led to recognition of 17 immunophenotypic markers allowing to identify cases ‘in agreement with MDS’. Moreover, data emphasizes the clinical utility of immunophenotyping in MDS diagnostics, given the high concordance between cytomorphology and the flow cytometric readout. Results from the current study challenge the application of the cytomorphologically defined cut-off of 5% blasts for flow cytometry and rather suggest a 3% cut-off for the latter.

Published
2023

78. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues—Recommendations from the European LeukemiaNet

Author

Austrian Science Fund, European Commission, Velden, Vincent H. J. van der, Preijers, Frank W. M. B., Johansson, Ulrika, Westers, Theresia M., Dunlop, Alan, Porwit, Anna, Béne, Marie C., Valent, Peter, Marvelde, Jeroen G. te, Wagner-Ballon, Orianne, Oelschlaegel, Uta, Saft, Leonie, Kordasti, Sharham, Ireland, Robin, Cremers, Eline M. P., Alhan, Canan, Duetz, Carolien, Hobo, Willemijn, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink Brodersen, Lisa, Font, Patricia, Loken, Michael R., Matarraz, Sergio, Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, Weiß, Elisabeth, Kern, Wolfgang, Austrian Science Fund, European Commission, Velden, Vincent H. J. van der, Preijers, Frank W. M. B., Johansson, Ulrika, Westers, Theresia M., Dunlop, Alan, Porwit, Anna, Béne, Marie C., Valent, Peter, Marvelde, Jeroen G. te, Wagner-Ballon, Orianne, Oelschlaegel, Uta, Saft, Leonie, Kordasti, Sharham, Ireland, Robin, Cremers, Eline M. P., Alhan, Canan, Duetz, Carolien, Hobo, Willemijn, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink Brodersen, Lisa, Font, Patricia, Loken, Michael R., Matarraz, Sergio, Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, Weiß, Elisabeth, and Kern, Wolfgang

Abstract

[Background]: Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. [Methods]: Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. [Results]: We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. [Conclusions]. These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.

Published
2023

79. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome:A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Author

van de Loosdrecht, Arjan A., Kern, Wolfgang, Porwit, Anna, Valent, Peter, Kordasti, Sharham, Cremers, Eline, Alhan, Canan, Duetz, Carolien, Dunlop, Alan, Hobo, Willemijn, Preijers, Frank, Wagner-Ballon, Orianne, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink-Brodersen, Lisa, Font, Patricia, Johansson, Ulrika, Loken, Michael R., te Marvelde, Jeroen G., Matarraz, Sergio, Ogata, Kiyoyuki, Oelschlaegel, Uta, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Béné, Marie C., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, van der Velden, Vincent H.J., Westers, Theresia M., Saft, Leonie, Ireland, Robin, van de Loosdrecht, Arjan A., Kern, Wolfgang, Porwit, Anna, Valent, Peter, Kordasti, Sharham, Cremers, Eline, Alhan, Canan, Duetz, Carolien, Dunlop, Alan, Hobo, Willemijn, Preijers, Frank, Wagner-Ballon, Orianne, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink-Brodersen, Lisa, Font, Patricia, Johansson, Ulrika, Loken, Michael R., te Marvelde, Jeroen G., Matarraz, Sergio, Ogata, Kiyoyuki, Oelschlaegel, Uta, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Béné, Marie C., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, van der Velden, Vincent H.J., Westers, Theresia M., Saft, Leonie, and Ireland, Robin

Abstract

This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

Published
2023

80. Flow cytometric analysis of myelodysplasia:Pre-analytical and technical issues—Recommendations from the European LeukemiaNet

Author

van der Velden, Vincent H.J., Preijers, Frank, Johansson, Ulrika, Westers, Theresia M., Dunlop, Alan, Porwit, Anna, Béné, Marie C., Valent, Peter, te Marvelde, Jeroen, Wagner-Ballon, Orianne, Oelschlaegel, Uta, Saft, Leonie, Kordasti, Sharham, Ireland, Robin, Cremers, Eline, Alhan, Canan, Duetz, Carolien, Hobo, Willemijn, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenshink-Brodersen, Lisa, Font, Patricia, Loken, Michael R., Matarraz, Sergio, Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, Weiß, Elisabeth, Kern, Wolfgang, van de Loosdrecht, Arjan, van der Velden, Vincent H.J., Preijers, Frank, Johansson, Ulrika, Westers, Theresia M., Dunlop, Alan, Porwit, Anna, Béné, Marie C., Valent, Peter, te Marvelde, Jeroen, Wagner-Ballon, Orianne, Oelschlaegel, Uta, Saft, Leonie, Kordasti, Sharham, Ireland, Robin, Cremers, Eline, Alhan, Canan, Duetz, Carolien, Hobo, Willemijn, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenshink-Brodersen, Lisa, Font, Patricia, Loken, Michael R., Matarraz, Sergio, Ogata, Kiyoyuki, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, Weiß, Elisabeth, Kern, Wolfgang, and van de Loosdrecht, Arjan

Abstract

Background: Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. Methods: Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. Results: We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. Conclusions: These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.

Published
2023

81. B-lineage acute lymphoblastic leukemia causes cell-autonomous defects in long-term hematopoietic stem cell function

Author

Jensen, Christina T., Åhsberg, Josefine, Tingvall-Gustafsson, Johanna, Somasundaram, Rajesh, Lang, Stefan, Ungerback, Jonas, Porwit, Anna, Soneji, Shamit, Sigvardsson, Mikael, Jensen, Christina T., Åhsberg, Josefine, Tingvall-Gustafsson, Johanna, Somasundaram, Rajesh, Lang, Stefan, Ungerback, Jonas, Porwit, Anna, Soneji, Shamit, and Sigvardsson, Mikael

Abstract

Funding Agencies|Swedish Childhood Cancer Foundation; Swedish Cancer Society; Swedish Research Council

Published
2023
Full Text
View/download PDF

82. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Author

European Commission, Loosdrecht, Arjan A. Van De, Kern, Wolfgang, Porwit, Anna, Valent, Peter, Kordasti, Sharham, Cremers, Eline M. P., Alhan, Canan, Duetz, Carolien, Dunlop, Alan, Hobo, Willemijn, Preijers, Frank W. M. B., Wagner-Ballon, Orianne, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink-Brodersen, Lisa, Font, Patricia, Johansson, Ulrika, Loken, Michael R., Marvelde, Jeroen G. te, Matarraz, Sergio, Ogata, Kiyoyuki, Oelschlaegel, Uta, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Béne, Marie C., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, Velden, Vincent H. J. van der, Westers, Theresia M., Saft, Leonie, Ireland, Robin, European Commission, Loosdrecht, Arjan A. Van De, Kern, Wolfgang, Porwit, Anna, Valent, Peter, Kordasti, Sharham, Cremers, Eline M. P., Alhan, Canan, Duetz, Carolien, Dunlop, Alan, Hobo, Willemijn, Preijers, Frank W. M. B., Wagner-Ballon, Orianne, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink-Brodersen, Lisa, Font, Patricia, Johansson, Ulrika, Loken, Michael R., Marvelde, Jeroen G. te, Matarraz, Sergio, Ogata, Kiyoyuki, Oelschlaegel, Uta, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise A., Béne, Marie C., Della Porta, Matteo G., Burbury, Kate, Bellos, Frauke, Velden, Vincent H. J. van der, Westers, Theresia M., Saft, Leonie, and Ireland, Robin

Abstract

This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

Published
2023

83. Updated T2K measurements of muon neutrino and antineutrino disappearance using 3.6 $\times$ 10$^{21}$ protons on target

Author

Ramírez, M. A., Abe, K., Akhlaq, N., Akutsu, R., Ali, A., Monsalve, S. Alonso, Alt, C., Andreopoulos, C., Antonova, M., Aoki, S., Arihara, T., Asada, Y., Ashida, Y., Atkin, E. T., Barbi, M., Barker, G. J., Barr, G., Barrow, D., Batkiewicz-Kwasniak, M., Bench, F., Berardi, V., Berns, L., Bhadra, S., Blanchet, A., Blondel, A., Bolognesi, S., Bonus, T., Bordoni, S., Boyd, S. B., Bravar, A., Bronner, C., Bron, S., Bubak, A., Avanzini, M. Buizza, Carretero, J. A. Caballero, Calabria, N. F., Cao, S., Carabadjac, D., Carter, A. J., Cartwright, S. L., Catanesi, M. G., Cervera, A., Chakrani, J., Cherdack, D., Chong, P. S., Christodoulou, G., Chvirova, A., Cicerchia, M., Coleman, J., Collazuol, G., Cook, L., Cudd, A., Dalmazzone, C., Daret, T., Davydov, Yu. I., De Roeck, A., De Rosa, G., Dealtry, T., Delogu, C. C., Densham, C., Dergacheva, A., Di Lodovico, F., Dolan, S., Douqa, D., Doyle, T. A., Drapier, O., Dumarchez, J., Dunne, P., Dygnarowicz, K., Eguchi, A., Emery-Schrenk, S., Erofeev, G., Ershova, A., Eurin, G., Fedorova, D., Fedotov, S., Feltre, M., Finch, A. J., Aguirre, G. A. Fiorentini, Fiorillo, G., Fitton, M. D., Patiño, J. M. Franco, Friend, M., Fujii, Y., Fukuda, Y., Fusshoeller, K., Giannessi, L., Giganti, C., Glagolev, V., Gonin, M., Rosa, J. González, Goodman, E. A. G., Gorin, A., Grassi, M., Guigue, M., Hadley, D. R., Haigh, J. T., Hamacher-Baumann, P., Harris, D. A., Hartz, M., Hasegawa, T., Hassani, S., Hastings, N. C., Hayato, Y., Henaff, D., Hiramoto, A., Hogan, M., Holeczek, J., Holin, A., Holvey, T., Van, N. T. Hong, Honjo, T., Iacob, F., Ichikawa, A. K., Ikeda, M., Ishida, T., Ishitsuka, M., Israel, H. T., Iwamoto, K., Izmaylov, A., Izumi, N., Jakkapu, M., Jamieson, B., Jenkins, S. J., Jesús-Valls, C., Jiang, J. J., Jonsson, P., Joshi, S., Jung, C. K., Jurj, P. B., Kabirnezhad, M., Kaboth, A. C., Kajita, T., Kakuno, H., Kameda, J., Kasetti, S. P., Kataoka, Y., Katayama, Y., Katori, T., Kawaue, M., Kearns, E., Khabibullin, M., Khotjantsev, A., Kikawa, T., Kikutani, H., King, S., Kiseeva, V., Kisiel, J., Kobata, T., Kobayashi, T., Koch, L., Kodama, S., Konaka, A., Kormos, L. L., Koshio, Y., Kostin, A., Koto, T., Kowalik, K., Kudenko, Y., Kudo, Y., Kuribayashi, S., Kurjata, R., Kutter, T., Kuze, M., La Commara, M., Labarga, L., Lachner, K., Lagoda, J., Lakshmi, S. M., James, M. Lamers, Lamoureux, M., Langella, A., Laporte, J. -F., Last, D., Latham, N., Laveder, M., Lavitola, L., Lawe, M., Lee, Y., Lin, C., Lin, S. -K., Litchfield, R. P., Liu, S. L., Li, W., Longhin, A., Long, K. R., Moreno, A. Lopez, Ludovici, L., Lu, X., Lux, T., Machado, L. N., Magaletti, L., Mahn, K., Malek, M., Mandal, M., Manly, S., Marino, A. D., Marti-Magro, L., Martin, D. G. R., Martini, M., Martin, J. F., Maruyama, T., Matsubara, T., Matveev, V., Mauger, C., Mavrokoridis, K., Mazzucato, E., McCauley, N., McElwee, J., McFarland, K. S., McGrew, C., McKean, J., Mefodiev, A., Megias, G. D., Mehta, P., Mellet, L., Metelko, C., Mezzetto, M., Miller, E., Minamino, A., Mineev, O., Mine, S., Miura, M., Bueno, L. Molina, Moriyama, S., Morrison, P., Mueller, Th. A., Munford, D., Munteanu, L., Nagai, K., Nagai, Y., Nakadaira, T., Nakagiri, K., Nakahata, M., Nakajima, Y., Nakamura, A., Nakamura, H., Nakamura, K., Nakamura, K. D., Nakano, Y., Nakayama, S., Nakaya, T., Nakayoshi, K., Naseby, C. E. R., Ngoc, T. V., Nguyen, V. Q., Niewczas, K., Nishimori, S., Nishimura, Y., Nishizaki, K., Nosek, T., Nova, F., Novella, P., Nugent, J. C., O'Keeffe, H. M., O'Sullivan, L., Odagawa, T., Ogawa, T., Okada, R., Okumura, K., Okusawa, T., Ospina, N., Owen, R. A., Oyama, Y., Palladino, V., Paolone, V., Pari, M., Parlone, J., Parsa, S., Pasternak, J., Pavin, M., Payne, D., Penn, G. C., Pershey, D., Pickering, L., Pidcott, C., Pintaudi, G., Pistillo, C., Popov, B., Porwit, K., Posiadala-Zezula, M., Prabhu, Y. S., Pupilli, F., Quilain, B., Radermacher, T., Radicioni, E., Radics, B., Ratoff, P. N., Reh, M., Riccio, C., Rondio, E., Roth, S., Rubbia, A., Ruggeri, A. C., Ruggles, C. A., Rychter, A., Sakashita, K., Sánchez, F., Santucci, G., Schloesser, C. M., Scholberg, K., Scott, M., Seiya, Y., Sekiguchi, T., Sekiya, H., Sgalaberna, D., Shaikhiev, A., Shaker, F., Shiozawa, M., Shorrock, W., Shvartsman, A., Skrobova, N., Skwarczynski, K., Smyczek, D., Smy, M., Sobczyk, J. T., Sobel, H., Soler, F. J. P., Sonoda, Y., Speers, A. J., Spina, R., Suslov, I. A., Suvorov, S., Suzuki, A., Suzuki, S. Y., Suzuki, Y., Sztuc, A. A., Tada, M., Tairafune, S., Takayasu, S., Takeda, A., Takeuchi, Y., Takifuji, K., Tanaka, H. K., Tanihara, Y., Tani, M., Teklu, A., Tereshchenko, V. V., Teshima, N., Thamm, N., Thompson, L. F., Toki, W., Touramanis, C., Towstego, T., Tsui, K. M., Tsukamoto, T., Tzanov, M., Uchida, Y., Vagins, M., Vargas, D., Vasseur, G., Vilela, C., Villa, E., Vinning, W. G. S., Virginet, U., Vladisavljevic, T., Wachala, T., Walsh, J. G., Wang, Y., Wan, L., Wark, D., Wascko, M. O., Weber, A., Wendell, R., Wilking, M. J., Wilkinson, C., Wilson, J. R., Wood, K., Wret, C., Xia, J., Xu, Y. -h., Yamamoto, K., Yamamoto, T., Yanagisawa, C., Yang, G., Yano, T., Yasutome, K., Yershov, N., Yevarouskaya, U., Yokoyama, M., Yoshimoto, Y., Yoshimura, N., Yu, M., Zaki, R., Zalewska, A., Zalipska, J., Zaremba, K., Zarnecki, G., Zhao, X., Zhu, T., Ziembicki, M., Zimmerman, E. D., Zito, M., Zsoldos, S., Laboratoire de Physique Nucléaire et de Hautes Énergies (LPNHE (UMR_7585)), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherches sur les lois Fondamentales de l'Univers (IRFU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Laboratoire Leprince-Ringuet (LLR), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-École polytechnique (X)-Centre National de la Recherche Scientifique (CNRS), and T2K

Subjects
hep-ex, J-PARC Lab, FOS: Physical sciences, neutrino, oscillation, KAMIOKANDE, High Energy Physics - Experiment, antineutrino, oscillation, symmetry, violation, flux, High Energy Physics - Experiment (hep-ex), near detector, muon, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], CPT, violation, antineutrino, beam, Particle Physics - Experiment
Abstract

International audience; Muon neutrino and antineutrino disappearance probabilities are identical in the standard three-flavor neutrino oscillation framework, but CPT violation and non-standard interactions can violate this symmetry. In this work we report the measurements of $\sin^{2} \theta_{23}$ and $\Delta m_{32}^2$ independently for neutrinos and antineutrinos. The aforementioned symmetry violation would manifest as an inconsistency in the neutrino and antineutrino oscillation parameters. The analysis discussed here uses a total of 1.97$\times$10$^{21}$ and 1.63$\times$10$^{21}$ protons on target taken with a neutrino and antineutrino beam respectively, and benefits from improved flux and cross-section models, new near detector samples and more than double the data reducing the overall uncertainty of the result. No significant deviation is observed, consistent with the standard neutrino oscillation picture.

Published
2023

84. First measurement of muon neutrino charged-current interactions on hydrocarbon without pions in the final state using multiple detectors with correlated energy spectra at T2K

Author

T2K Collaboration, Abe, K., Akhlaq, N., Akutsu, R., Ali, A., Monsalve, S. Alonso, Alt, C., Andreopoulos, C., Antonova, M., Aoki, S., Arihara, T., Asada, Y., Ashida, Y., Atkin, E. T., Barker, G. J., Barr, G., Barrow, D., Batkiewicz-Kwasniak, M., Bench, F., Berardi, V., Berns, L., Bhadra, S., Blanchet, A., Blondel, A., Bolognesi, S., Bonus, T., Bordoni, S., Boyd, S. B., Bravar, A., Bronner, C., Bron, S., Bubak, A., Avanzini, M. Buizza, Carretero, J. A. Caballero, Cao, S., Carter, A. J., Cartwright, S. L., Catanesi, M. G., Cervera, A., Chakrani, J., Cherdack, D., Christodoulou, G., Cicerchia, M., Coleman, J., Collazuol, G., Cook, L., Cudd, A., Dalmazzone, C., Davydov, Yu. I., De Roeck, A., De Rosa, G., Dealtry, T., Delogu, C. C., Densham, C., Dergacheva, A., Di Lodovico, F., Dolan, S., Douqa, D., Doyle, T. A., Drapier, O., Dumarchez, J., Dunne, P., Dygnarowicz, K., Eguchi, A., Emery-Schrenk, S., Ershova, A., Feltre, M., Finch, A. J., Aguirre, G. A. Fiorentini, Fiorillo, G., Patiño, J. M. Franco, Friend, M., Fujii, Y., Fukuda, Y., Fusshoeller, K., Giannessi, L., Giganti, C., Glagolev, V., Gonin, M., Rosa, J. González, Goodman, E. A. G., Gorin, A., Grassi, M., Guigue, M., Hadley, D. R., Haigh, J. T., Hamacher-Baumann, P., Harris, D. A., Hartz, M., Hasegawa, T., Hassani, S., Hastings, N. C., Hayato, Y., Hiramoto, A., Hogan, M., Holeczek, J., Holin, A., Holvey, T., Van, N. T. Hong, Honjo, T., Iacob, F., Ichikawa, A. K., Ikeda, M., Ishida, T., Ishitsuka, M., Israel, H. T., Izmaylov, A., Izumi, N., Jakkapu, M., Jamieson, B., Jenkins, S. J., Jesús-Valls, C., Jiang, J. J., Jonsson, P., Jung, C. K., Jurj, P. B., Kabirnezhad, M., Kaboth, A. C., Kajita, T., Kakuno, H., Kameda, J., Kasetti, S. P., Kataoka, Y., Katori, T., Kawaue, M., Kearns, E., Khabibullin, M., Khotjantsev, A., Kikawa, T., King, S., Kisiel, J., Kobata, T., Kobayashi, T., Koch, L., Konaka, A., Kormos, L. L., Koshio, Y., Kostin, A., Kowalik, K., Kudenko, Y., Kuribayashi, S., Kurjata, R., Kutter, T., Kuze, M., La Commara, M., Labarga, L., Lachner, K., Lagoda, J., Lakshmi, S. M., James, M. Lamers, Lamoureux, M., Langella, A., Last, D., Latham, N., Laveder, M., Lavitola, L., Lawe, M., Lee, Y., Lin, C., Lin, S. -K., Litchfield, R. P., Liu, S. L., Longhin, A., Long, K. R., Ludovici, L., Lu, X., Lux, T., Machado, L. N., Magaletti, L., Mahn, K., Malek, M., Mandal, M., Manly, S., Marino, A. D., Marti-Magro, L., Martin, D. G. R., Martini, M., Maruyama, T., Matsubara, T., Matveev, V., Mauger, C., Mavrokoridis, K., Mazzucato, E., McCauley, N., McElwee, J., McFarland, K. S., McGrew, C., Mefodiev, A., Megias, G. D., Mellet, L., Mezzetto, M., Minamino, A., Mineev, O., Mine, S., Miura, M., Bueno, L. Molina, Moriyama, S., Mueller, Th. A., Munford, D., Munteanu, L., Nagai, K., Nagai, Y., Nakadaira, T., Nakagiri, K., Nakahata, M., Nakajima, Y., Nakamura, A., Nakamura, H., Nakamura, K., Nakamura, K. D., Nakano, Y., Nakayama, S., Nakaya, T., Nakayoshi, K., Naseby, C. E. R., Ngoc, T. V., Nguyen, V. Q., Niewczas, K., Nishimura, Y., Nishizaki, K., Nova, F., Nugent, J. C., O'Keeffe, H. M., O'Sullivan, L., Odagawa, T., Ogawa, T., Okumura, K., Okusawa, T., Owen, R. A., Oyama, Y., Palladino, V., Paolone, V., Pari, M., Parlone, J., Parsa, S., Pasternak, J., Pavin, M., Payne, D., Penn, G. C., Pershey, D., Pickering, L., Pidcott, C., Pintaudi, G., Pistillo, C., Popov, B., Porwit, K., Posiadala-Zezula, M., Prabhu, Y. S., Pupilli, F., Quilain, B., Radermacher, T., Radicioni, E., Radics, B., Ratoff, P. N., Reh, M., Riccio, C., Rondio, E., Roth, S., Rubbia, A., Ruggeri, A. C., Ruggles, C. A., Rychter, A., Sakashita, K., Sánchez, F., Santucci, G., Schloesser, C. M., Scholberg, K., Scott, M., Seiya, Y., Sekiguchi, T., Sekiya, H., Sgalaberna, D., Shaikhiev, A., Shiozawa, M., Shorrock, W., Shvartsman, A., Skwarczynski, K., Smyczek, D., Smy, M., Sobczyk, J. T., Sobel, H., Soler, F. J. P., Sonoda, Y., Speers, A. J., Spina, R., Suslov, I. A., Suvorov, S., Suzuki, A., Suzuki, S. Y., Suzuki, Y., Sztuc, A. A., Tada, M., Tairafune, S., Takayasu, S., Takeda, A., Takeuchi, Y., Takifuji, K., Tanaka, H. K., Tani, M., Teklu, A., Tereshchenko, V. V., Teshima, N., Thamm, N., Thompson, L. F., Toki, W., Touramanis, C., Towstego, T., Tsui, K. M., Tsukamoto, T., Tzanov, M., Uchida, Y., Vagins, M., Vargas, D., Vasseur, G., Vilela, C., Villa, E., Vinning, W. G. S., Virginet, U., Vladisavljevic, T., Wachala, T., Walsh, J. G., Wang, Y., Wan, L., Wark, D., Wascko, M. O., Weber, A., Wendell, R., Wilking, M. J., Wilkinson, C., Wilson, J. R., Wood, K., Wret, C., Xia, J., Xu, Y. -h., Yamamoto, K., Yanagisawa, C., Yang, G., Yano, T., Yasutome, K., Yershov, N., Yevarouskaya, U., Yokoyama, M., Yoshimoto, Y., Yu, M., Zaki, R., Zalewska, A., Zalipska, J., Zaremba, K., Zarnecki, G., Zhao, X., Zhu, T., Ziembicki, M., Zimmerman, E. D., Zito, M., Zsoldos, S., Laboratoire de Physique Nucléaire et de Hautes Énergies (LPNHE (UMR_7585)), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherches sur les lois Fondamentales de l'Univers (IRFU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Laboratoire Leprince-Ringuet (LLR), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-École polytechnique (X)-Centre National de la Recherche Scientifique (CNRS), and T2K

Subjects
neutrino, energy spectrum, hep-ex, J-PARC Lab, neutrino, interaction, FOS: Physical sciences, neutrino nucleus, interaction, KAMIOKANDE, GeV, charged current, energy dependence, High Energy Physics - Experiment, neutrino, flux, High Energy Physics - Experiment (hep-ex), near detector, muon, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], Monte Carlo, Particle Physics - Experiment
Abstract

International audience; This paper reports the first measurement of muon neutrino charged-current interactions without pions in the final state using multiple detectors with correlated energy spectra at T2K. The data was collected on hydrocarbon targets using the off-axis T2K near detector (ND280) and the on-axis T2K near detector (INGRID) with neutrino energy spectra peaked at 0.6 GeV and 1.1 GeV respectively. The correlated neutrino flux presents an opportunity to reduce the impact of the flux uncertainty and to study the energy dependence of neutrino interactions. The extracted double-differential cross sections are compared to several Monte Carlo neutrino-nucleus interaction event generators showing the agreement between both detectors individually and with the correlated result.

Published
2023

88. Supernova model discrimination with hyper-kamiokande

Author

Y. Nagao, H. Tanaka, A. Minamino, B. Navarro-Garcia, Z. Xie, L. Nascimento Machado, J. Lagoda, M. Shinoki, S. Cuen-Rochin, Arman Esmaili, F. Ballester, S. Parsa, N. McCauley, Jung-Hyun Kim, K. Frankiewicz, L. L. Kormos, Masaki Ishitsuka, M. Malek, V. Valentino, N. Kazarian, T. Wachala, E. Drakopoulou, G. Grella, V. Paolone, L. F. Thompson, A. K. Tomatani-Sánchez, A. Blanchet, R. A. Wendell, John Ellis, J. Y. Kim, N. W. Prouse, O. V. Mineev, M. R. Vagins, T. Boschi, T. Lindner, J. González-Nuevo, Hiroshi Ito, N. Skrobova, M. La Commara, L. Gialanella, F. Orozco-Luna, T. Kumita, A. Garfagnini, S. H. Jeon, A. Dergacheva, Hiroaki Menjo, A. T. Suzuki, K. Okamoto, C. E. R. Naseby, J. F. Martin, T. Iijima, M. Mezzetto, G. Ricciardi, J. R. Wilson, P. Gumplinger, Y. Takemoto, G. Galinski, K. Zaremba, T. Nakadaira, D. Vivolo, A. Carroll, C. Vilela, A. Blondel, A. Rychter, T. A. Doyle, C. Garde, G. De Rosa, A. Oshlianskyi, Hiroyuki Sekiya, R. Matsumoto, G. Pastuszak, P. J. Rajda, F. Monrabal, Yoichi Asaoka, G. Díaz López, K. L. Stankevich, C. D. Shin, Y. Fukuda, Yuto Ashida, Michal Malinský, T. Suganuma, B. Radics, Kohta Murase, Marco Grassi, P. Mehta, F. Cafagna, Ahmed Ali, L. Koerich, Vincenzo Berardi, Etam Noah, F. J. P. Soler, Alan Cosimo Ruggeri, M. Kekic, G. Vasseur, S. Wronka, M. Thiesse, B. Ferrazzi, K. Iwamoto, Yu. Kudenko, Atsushi Takeda, Kendall Mahn, David Hadley, B. Roskovec, M. Bergevin, A. Korzenev, J.J. Gómez-Cadenas, M. Batkiewicz-Kwasniak, M. Tzanov, M. Ikeda, Federico Sanchez, W. Obrębski, H. S. Jo, Y. Takeuchi, Piotr Kalaczyński, S. Chakraborty, J. C. Nugent, S. King, P. Paganini, M. Miura, F. Ameli, D. N. Yeum, C. J. Metelko, Akito Araya, T. Kajita, M. Tanaka, I. T. Lim, L. Mellet, S. Y. Kim, S. Bolognesi, A. Bravar, J. S. Jang, D. Svirida, A. Fiorentini, J. Renner, M. Chabera, L. O'Sullivan, V. Herrero, F. Iacob, K. Nakamura, Ko Okumura, Lukasz Stawarz, N. Ogawa, Laura Bonavera, Y. Maekawa, Takatomi Yano, Ll. Marti, H. J. Rose, S. El Hedri, L. Maret, G. Zarnecki, L. Bernard, S. H. Seo, H. Nakamura, H. Ozaki, A. P. Kryukov, A. Popov, Hisakazu Minakata, M. Buizza Avanzini, P. Sarmah, K. Martens, Sergio Luis Suárez Gómez, Hiroaki Aihara, V. Lezaun, G. A. Cowan, C. Riccio, S. Garode, R. Akutsu, M. Lamers James, T. Nicholls, I. Alekseev, K. Kowalik, J. Kasperek, T. Zakrzewski, S. B. Kim, T. Kutter, Evan O'Connor, B. Jamieson, F. Nova, M. Barbi, Xianguo Lu, Y. Sonoda, M. Friend, Teppei Katori, L. H. V. Anthony, A. Shaikhiev, C. J. Densham, V. Gousy-Leblanc, I. Bandac, J. H. Choi, S. Sano, A. K. Ichikawa, Magda Cicerchia, S. Valder, S. Roth, J. Kameda, M. Zito, A. Vijayvargi, S. Nakai, Y. Kotsar, K. M. Tsui, K. Hoshina, K. K. Joo, C. Pastore, T. Marchi, K. Niewczas, K. Nakayoshi, G. Fiorillo, C. McGrew, P. F. Loverre, S. Playfer, G.D. Barr, L. Labarga, T. Kobayashi, E. S. Pinzon Guerra, André Rubbia, D. Karlen, Th. A. Mueller, L. Koch, F. J. Mora, M. M. Khabibullin, Hidekazu Kakuno, Yoshitaka Itow, H. K. Tanaka, P. Adrich, Jeong-Eun Lee, S. Samani, M. G. Catanesi, M. Yu, M. J. Wilking, Robert Svoboda, P. Mijakowski, N. Kolev, Yu. Onishchuk, A. Kato, J. M. Poutissou, C. Bronner, Yutaka Nakajima, B. Richards, C. Ruggles, M. Needham, P. Jonsson, Y. Hayato, S. Mine, A. Konaka, L. Munteanu, Kunio Inoue, O. Drapier, Kenneth Long, M. McCarthy, T. Kinoshita, G. Tortone, Yuuki Nakano, T. Feusels, N. Izumi, Reetanjali Moharana, T. Dealtry, S. Hassani, G. Pronost, K. Sakashita, J. G. Learned, H. M. O'Keeffe, Shintaro Ito, E. Rondio, Toru Ogitsu, D. A. Patel, Tatiana Ovsiannikova, M. Guigue, Yusuke Koshio, T. Matsubara, S. M. Stellacci, R. J. Wilkes, G. Santucci, S. Y. Suzuki, S. D. Rountree, K. Zietara, A. A. Quiroga, M. Jakkapu, A. Boiano, L. Berns, M. O. Wascko, M. M. Vyalkov, K. Porwit, M. Taani, A. Evangelisti, I. Sashima, Michal Dziewiecki, J. Feng, Y. Seiya, M. Yonenaga, B. Spisso, B. W. Pointon, C. M. Mollo, N. Booth, S. V. Cao, N. Ospina, A. J. Finch, V. Takhistov, E. Radicioni, P. Przewlocki, S. Nakayama, S. Yen, T. Sekiguchi, Yudai Suwa, J. M. Calvo-Mozota, S. Zsoldos, C. Checchia, M. Posiadala-Zezula, E. O'Sullivan, Janusz Marzec, F. Retiere, Jan T. Sobczyk, P. Migliozzi, S. Borjabad, I. Di Palma, John Hill, K. A. Kouzakov, D. L. Wark, L. Cook, D. Sgalaberna, E. W. Miller, M. Lamoureux, M. Y. Pac, S. Russo, S. L. Cartwright, Yasunari Suzuki, D. Bose, B. Zaldivar, D. Martin, Dongsu Ryu, Z. Shan, S. Miki, M. Jiang, J. Kisiel, N. Yershov, M. Matusiak, C. Pea-Garay, K. Sato, Jesús Daniel Santos, Y. Yamaguchi, D. Bravo-Berguo, Chad Finley, T. Tashiro, Lawrence D. Brown, A. Gorin, Hiromasa Tanaka, M. Ziembicki, T. Vladisavljevic, J. Zalipska, J. Insler, C. Yanagisawa, Abinash Medhi, L. Kravchuk, W. Idrissi Ibnsalih, Hirokazu Ishino, J. Bian, K. Magar, S. Cebrian, Philippe Mermod, R. Gornea, Juan Pedro Ochoa-Ricoux, Sergei Fedotov, S. Izumiyama, C. Bozza, R. Esteve, Seiko Hirota, T. Tsukamoto, K. Skwarczynski, E. De la Fuente, T. Kikawa, M. Gonin, J. Xia, Intae Yu, Gareth J. Barker, A. Marinelli, E. Kearns, L. Lavitola, Michal Ostrowski, N. Deshmukh, Y. Kataoka, F. d. M. Blaszczyk, Carsten Rott, C. Mariani, T. Ishida, Roberto Spina, J. W. Seo, Masashi Yokoyama, F. Gramegna, K. Hultqvist, G. Collazuol, P. Spradlin, Gus Sinnis, A. Takenaka, T. Xin, M. Bellato, Yuki Fujii, Mark Scott, J. A. Hernando-Morata, P. Ferrario, A. Buchowicz, S. J. Jenkins, J. Walker, J. Toledo, Pablo Fernandez, Sandhya Choubey, S. Emery, A. Mefodiev, R.P. Kurjata, M. Mongelli, J. Dumarchez, Tsuyoshi Nakaya, M. Antonova, M. Danilov, M. Feely, A. Holin, Ara Ioannisian, B. A. Popov, K Stopa, W. G. S. Vinning, M. L. Sánchez, Masato Shiozawa, L. Ludovici, J. Gao, S. Bhadra, Koji Ishidoshiro, Hiroshi Nunokawa, V. Aushev, M. Hartz, I. Shimizu, C. S. Moon, M. B. Smy, S. Matsuno, I. Anghel, J. Migenda, T. Mondal, F. Di Lodovico, M. Tada, D. J. Payne, M. Kuze, N. C. Hastings, P. Di Meo, Y. Nishimura, M. Inomoto, L. Magaletti, C. Giganti, A. Klekotko, Patrick Dunne, J. Yoo, M. C. Sanchez, A. N. Khotjantsev, Kyujin Kwak, Lars Eklund, M. Lawe, A. Mitra, H. W. Sobel, Jürgen Pozimski, Yasuhiro Makida, A. Bubak, Jaroslaw Pasternak, B. Quilain, R. Leitner, Marco Laveder, J. P. Coleman, N. F. Calabria, H. I. Jang, S. B. Boyd, Moon Moon Devi, M. Fitton, M. Harada, Artur F. Izmaylov, J. McElwee, Shunsaku Horiuchi, P. de Perio, K. Nakagiri, Y. Kano, M. Rescigno, S. Moriyama, Masayuki Nakahata, C. Pidcott, Y. Uchida, V. Palladino, A. Longhin, A. Shaykina, Michelangelo Pari, Akimichi Taketa, Yuichi Oyama, S. Suvorov, R. P. Litchfield, D. H. Moon, Katsuki Hiraide, M. Pavin, M. Koga, R. B. Vogelaar, Enrique Fernandez-Martinez, B. L. Hartfiel, Koji Yamamoto, K. Ohta, K. Abe, Alexander Studenikin, E. Mazzucato, Elisa Bernardini, Abe, K., Adrich, P., Aihara, H., Akutsu, R., Alekseev, I., Ali, A., Ameli, F., Anghel, I., Anthony, L. H. V., Antonova, M., Araya, A., Asaoka, Y., Ashida, Y., Aushev, V., Ballester, F., Bandac, I., Barbi, M., Barker, G. J., Barr, G., Batkiewicz-Kwasniak, M., Bellato, M., Berardi, V., Bergevin, M., Bernard, L., Bernardini, E., Berns, L., Bhadra, S., Bian, J., Blanchet, A., Blaszczyk, F. D. M., Blondel, A., Boiano, A., Bolognesi, S., Bonavera, L., Booth, N., Borjabad, S., Boschi, T., Bose, D., Boyd, S. B., Bozza, C., Bravar, A., Bravo-Berguo, D., Bronner, C., Brown, L., Bubak, A., Buchowicz, A., Buizza Avanzini, M., Cafagna, F. S., Calabria, N. F., Calvo-Mozota, J. M., Cao, S., Cartwright, S. L., Carroll, A., Catanesi, M. G., Cebrian, S., Chabera, M., Chakraborty, S., Checchia, C., Choi, J. H., Choubey, S., Cicerchia, M., Coleman, J., Collazuol, G., Cook, L., Cowan, G., Cuen-Rochin, S., Danilov, M., Diaz Lopez, G., De La Fuente, E., De Perio, P., De Rosa, G., Dealtry, T., Densham, C. J., Dergacheva, A., Deshmukh, N., Devi, M. M., Di Lodovico, F., Di Meo, P., Di Palma, I., Doyle, T. A., Drakopoulou, E., Drapier, O., Dumarchez, J., Dunne, P., Dziewiecki, M., Eklund, L., El Hedri, S., Ellis, J., Emery, S., Esmaili, A., Esteve, R., Evangelisti, A., Feely, M., Fedotov, S., Feng, J., Fernandez, P., Fernandez-Martinez, E., Ferrario, P., Ferrazzi, B., Feusels, T., Finch, A., Finley, C., Fiorentini, A., Fiorillo, G., Fitton, M., Frankiewicz, K., Friend, M., Fujii, Y., Fukuda, Y., Galinski, G., Gao, J., Garde, C., Garfagnini, A., Garode, S., Gialanella, L., Giganti, C., Gomez-Cadenas, J. J., Gonin, M., Gonzalez-Nuevo, J., Gorin, A., Gornea, R., Gousy-Leblanc, V., Gramegna, F., Grassi, M., Grella, G., Guigue, M., Gumplinger, P., Hadley, D. R., Harada, M., Hartfiel, B., Hartz, M., Hassani, S., Hastings, N. C., Hayato, Y., Hernando-Morata, J. A., Herrero, V., Hill, J., Hiraide, K., Hirota, S., Holin, A., Horiuchi, S., Hoshina, K., Hultqvist, K., Iacob, F., Ichikawa, A. K., Idrissi Ibnsalih, W., Iijima, T., Ikeda, M., Inomoto, M., Inoue, K., Insler, J., Ioannisian, A., Ishida, T., Ishidoshiro, K., Ishino, H., Ishitsuka, M., Ito, H., Ito, S., Itow, Y., Iwamoto, K., Izmaylov, A., Izumi, N., Izumiyama, S., Jakkapu, M., Jamieson, B., Jang, H. I., Jang, J. S., Jenkins, S. J., Jeon, S. H., Jiang, M., Jo, H. S., Jonsson, P., Joo, K. K., Kajita, T., Kakuno, H., Kameda, J., Kano, Y., Kalaczynski, P., Karlen, D., Kasperek, J., Kataoka, Y., Kato, A., Katori, T., Kazarian, N., Kearns, E., Khabibullin, M., Khotjantsev, A., Kikawa, T., Kekic, M., Kim, J. H., Kim, J. Y., Kim, S. B., Kim, S. Y., King, S., Kinoshita, T., Kisiel, J., Klekotko, A., Kobayashi, T., Koch, L., Koga, M., Koerich, L., Kolev, N., Konaka, A., Kormos, L. L., Koshio, Y., Korzenev, A., Kotsar, Y., Kouzakov, K. A., Kowalik, K. L., Kravchuk, L., Kryukov, A. P., Kudenko, Y., Kumita, T., Kurjata, R., Kutter, T., Kuze, M., Kwak, K., La Commara, M., Labarga, L., Lagoda, J., Lamers James, M., Lamoureux, M., Laveder, M., Lavitola, L., Lawe, M., Learned, J. G., Lee, J., Leitner, R., Lezaun, V., Lim, I. T., Lindner, T., Litchfield, R. P., Long, K. R., Longhin, A., Loverre, P., Lu, X., Ludovici, L., Maekawa, Y., Magaletti, L., Magar, K., Mahn, K., Makida, Y., Malek, M., Malinsky, M., Marchi, T., Maret, L., Mariani, C., Marinelli, A., Martens, K., Marti, L., Martin, J. F., Martin, D., Marzec, J., Matsubara, T., Matsumoto, R., Matsuno, S., Matusiak, M., Mazzucato, E., Mccarthy, M., Mccauley, N., Mcelwee, J., Mcgrew, C., Mefodiev, A., Medhi, A., Mehta, P., Mellet, L., Menjo, H., Mermod, P., Metelko, C., Mezzetto, M., Migenda, J., Migliozzi, P., Mijakowski, P., Miki, S., Miller, E. W., Minakata, H., Minamino, A., Mine, S., Mineev, O., Mitra, A., Miura, M., Moharana, R., Mollo, C. M., Mondal, T., Mongelli, M., Monrabal, F., Moon, D. H., Moon, C. S., Mora, F. J., Moriyama, S., Mueller, T. A., Munteanu, L., Murase, K., Nagao, Y., Nakadaira, T., Nakagiri, K., Nakahata, M., Nakai, S., Nakajima, Y., Nakamura, K., Nakamura, K. I., Nakamura, H., Nakano, Y., Nakaya, T., Nakayama, S., Nakayoshi, K., Nascimento Machado, L., Naseby, C. E. R., Navarro-Garcia, B., Needham, M., Nicholls, T., Niewczas, K., Nishimura, Y., Noah, E., Nova, F., Nugent, J. C., Nunokawa, H., Obrebski, W., Ochoa-Ricoux, J. P., O'Connor, E., Ogawa, N., Ogitsu, T., Ohta, K., Okamoto, K., O'Keeffe, H. M., Okumura, K., Onishchuk, Y., Orozco-Luna, F., Oshlianskyi, A., Ospina, N., Ostrowski, M., O'Sullivan, E., O'Sullivan, L., Ovsiannikova, T., Oyama, Y., Ozaki, H., Pac, M. Y., Paganini, P., Palladino, V., Paolone, V., Pari, M., Parsa, S., Pasternak, J., Pastore, C., Pastuszak, G., Patel, D. A., Pavin, M., Payne, D., Pea-Garay, C., Pidcott, C., Pinzon Guerra, E., Playfer, S., Pointon, B. W., Popov, A., Popov, B., Porwit, K., Posiadala-Zezula, M., Poutissou, J. -M., Pozimski, J., Pronost, G., Prouse, N. W., Przewlocki, P., Quilain, B., Quiroga, A. A., Radicioni, E., Radics, B., Rajda, P. J., Renner, J., Rescigno, M., Retiere, F., Ricciardi, G., Riccio, C., Richards, B., Rondio, E., Rose, H. J., Roskovec, B., Roth, S., Rott, C., Rountree, S. D., Rubbia, A., Ruggeri, A. C., Ruggles, C., Russo, S., Rychter, A., Ryu, D., Sakashita, K., Samani, S., Sanchez, F., Sanchez, M. L., Sanchez, M. C., Sano, S., Santos, J. D., Santucci, G., Sarmah, P., Sashima, I., Sato, K., Scott, M., Seiya, Y., Sekiguchi, T., Sekiya, H., Seo, J. W., Seo, S. H., Sgalaberna, D., Shaikhiev, A., Shan, Z., Shaykina, A., Shimizu, I., Shin, C. D., Shinoki, M., Shiozawa, M., Sinnis, G., Skrobova, N., Skwarczynski, K., Smy, M. B., Sobczyk, J., Sobel, H. W., Soler, F. J. P., Sonoda, Y., Spina, R., Spisso, B., Spradlin, P., Stankevich, K. L., Stawarz, L., Stellacci, S. M., Stopa, K., Studenikin, A. I., Suarez Gomez, S. L., Suganuma, T., Suvorov, S., Suwa, Y., Suzuki, A. T., Suzuki, S. Y., Suzuki, Y., Svirida, D., Svoboda, R., Taani, M., Tada, M., Takeda, A., Takemoto, Y., Takenaka, A., Taketa, A., Takeuchi, Y., Takhistov, V., Tanaka, H., Tanaka, H. A., Tanaka, H. I., Tanaka, M., Tashiro, T., Thiesse, M., Thompson, L. F., Toledo, J., Tomatani-Sanchez, A. K., Tortone, G., Tsui, K. M., Tsukamoto, T., Tzanov, M., Uchida, Y., Vagins, M. R., Valder, S., Valentino, V., Vasseur, G., Vijayvargi, A., Vilela, C., Vinning, W. G. S., Vivolo, D., Vladisavljevic, T., Vogelaar, R. B., Vyalkov, M. M., Wachala, T., Walker, J., Wark, D., Wascko, M. O., Wendell, R. A., Wilkes, R. J., Wilking, M. J., Wilson, J. R., Wronka, S., Xia, J., Xie, Z., Xin, T., Yamaguchi, Y., Yamamoto, K., Yanagisawa, C., Yano, T., Yen, S., Yershov, N., Yeum, D. N., Yokoyama, M., Yonenaga, M., Yoo, J., Yu, I., Yu, M., Zakrzewski, T., Zaldivar, B., Zalipska, J., Zaremba, K., Zarnecki, G., Ziembicki, M., Zietara, K., Zito, M., Zsoldos, S., Laboratoire Leprince-Ringuet (LLR), Centre National de la Recherche Scientifique (CNRS)-École polytechnique (X)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), Laboratoire de Physique Nucléaire et de Hautes Énergies (LPNHE (UMR_7585)), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Astrophysique Interprétation Modélisation (AIM (UMR_7158 / UMR_E_9005 / UM_112)), Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7), Hyper-Kamiokande, Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-École polytechnique (X)-Centre National de la Recherche Scientifique (CNRS), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Astrophysique Interprétation Modélisation (AIM (UMR7158 / UMR_E_9005 / UM_112)), and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Physics - Instrumentation and Detectors, 09.- Desarrollar infraestructuras resilientes, promover la industrialización inclusiva y sostenible, y fomentar la innovación, KAMIOKANDE, Astrophysics, 01 natural sciences, neutrino: flux, High Energy Physics - Experiment, High Energy Physics - Experiment (hep-ex), neutrino, accretion, black hole, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], Core-collapse supernovae, neutron star, Monte Carlo, physics.ins-det, 010303 astronomy & astrophysics, astro-ph.HE, High Energy Astrophysical Phenomena (astro-ph.HE), Physics, Instrumentation and Detectors (physics.ins-det), 16. Peace & justice, Supernova, neutrino: detector, 07.- Asegurar el acceso a energías asequibles, fiables, sostenibles y modernas para todos, supernova, neutrino astronomy, neutrino physics, Neutrino detector, Neutrino, Astrophysics - Instrumentation and Methods for Astrophysics, Astrophysics - High Energy Astrophysical Phenomena, supernova: collapse, Astrophysics::High Energy Astrophysical Phenomena, FOS: Physical sciences, Observable universe, Astrophysics::Cosmology and Extragalactic Astrophysics, Hyper-Kamiokande, 0103 physical sciences, [PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det], High energy physics, Instrumentation and Methods for Astrophysics (astro-ph.IM), High Energy Astrophysical Phenomena, Astrophysics::Galaxy Astrophysics, hep-ex, 010308 nuclear & particles physics, supernova: model, Astronomy and Astrophysics, Galaxy, Black hole, Neutron star, Space and Planetary Science, neutrino: burst, galaxy, Neutrino astronomy, [PHYS.ASTR]Physics [physics]/Astrophysics [astro-ph], astro-ph.IM
Abstract

Autorzy: Abe K., Adrich P., Aihara H., Akutsu, R., Alekseev I., Ali A. , Ameli F., Anghel I., Anthony L. H. V., Antonova M. , Araya A., Asaoka Y., Ashida Y., Aushev V., Ballester F., Bandac I., Barbi M., Barker G. J., Barr G., Batkiewicz-Kwasniak M., Bellato M., Berardi V., Bergevin M., Bernard L., Bernardini E., Berns L., Bhadra S., Bian J., Blanchet A., Blaszczyk F. d. M., Blonde A., Boiano A., Bolognesi S., Bonavera L., Booth N., Borjabad S., Boschi, T., Bose D., Boyd S . B., Bozza C., Bravar A., Bravo-Berguño D., Bronner C., Brown L., Bubak Arkadiusz, Buchowicz A., Buizza Avanzini M., Cafagna F. S., Calabria N. F., Calvo-Mozota J. M., Cao S., Cartwright S.L., Carroll A., Catanesi M. G., Cebriàn, S., Chabera M., Chakraborty, S., Checchia C., Choi J.H., Choubey S., Cicerchia M., Coleman J., Collazuol G., Cook L., Cowan G., Cuen-Rochin, S., Danilov M., Díaz López G., De la Fuente E., de Perio P., De Rosa G., Dealtry T., Densham C. J., Dergacheva A., Deshmukh N., Devi M. M., Di Lodovico F., Di Meo, P., Di Palma I., Doyle T. A., Drakopoulou E., Drapier O., Dumarchez J., Dunne P., Dziewiecki M., Eklund L., El Hedri S., Ellis J., Emery S., Esmaili A., Esteve R., Evangelisti A., Feely M., Fedotov S., Feng J., Fernandez P., Fernández-Martinez E., Ferrario P., Ferrazzi,B., Feusels T., Finch A., Finley C., Fiorentini A., Fiorillo G., Fitton M., Frankiewicz K., Friend M., Fujii Y., Fukuda Y., Galinski G., Gao J., Garde C., Garfagnini A., Garode S., Gialanella L., Giganti C., Gomez-Cadenas J.J., Gonin M., González-Nuevo J., Gorin A., Gornea R., Gousy-Leblanc V. Gramegna F. Grassi M. Grella G. Guigue M. Gumplinger P. Hadley D.R. Harada M., Hartfiel B., Hartz M., Hassani S., Hastings N.C., Hayato Y., Hernando-Morata J.A., Herrero V., Hill J., Hiraide K., Hirota S., Holin A., Horiuchi S., Hoshina K., Hultqvist K., Iacob F., Ichikawa A.K., Idrissi Ibnsalih W., Iijima T., Ikeda M., Inomoto M., Inoue K., Insler J., Ioannisian A., Ishida T., Ishidoshiro K., Ishino H., Ishitsuka M., Ito H., Ito S., Itow Y., Iwamoto K., Izmaylov A., Izumi N., Izumiyama S., Jakkapu M., Jamieson B., Jang H.I., Jang J.S., Jenkins S.J., Jeon S.H., Jiang M., Jo H.S., Jonsson P., Joo K.K., Kajita T., Kakuno H., Kameda J., Kano Y., Kalaczynski P., Karlen D., Kasperek J., Kataoka Y., Kato A., Katori T., Kazarian N., Kearns E., Khabibullin M., Khotjantsev A., Kikawa T., Kekic M., Kim J.H., Kim J.Y., Kim S.B., Kim S.Y., King S., Kinoshita T., Kisiel Jan, Klekotko A., Kobayashi T., Koch L., Koga M., Koerich L., Kolev N., Konaka A., Kormos L.L., Koshio Y., Korzenev A., Kotsar Y., Kouzakov K.A., Kowalik K.L., Kravchuk L., Kryukov A.P., Kudenko Y., Kumita T., Kurjata R., Kutter T., Kuze M., Kwak K., La Commara M., Labarga L., Lagoda J., Lamers James J., Lamoureux M., Laveder M., Lavitola L., Lawe M., Learned J.G., Lee J., Leitner R., Lezaun V., Lim I.T., Lindner T., Litchfield R.P., Long K.R., Longhin A., Loverre P., Lu X., Ludovici L., Maekawa Y., Magaletti L., Magar K., Mahn K., Makida Y., Malek M., Malinský M., Marchi T., Maret L., Mariani C., Marinelli A., Martens K., Marti L., Martin J.F. Martin D., Marzec J., Matsubara T., Matsumoto R., Matsuno S., Matusiak M., Mazzucato E., McCarthy M., McCauley N., McElwee J., McGrew C., Mefodiev A., Medhi A., Mehta P., Mellet L., Menjo H., Mermod P., Metelko C., Mezzetto M., Migenda J., Migliozzi P., Mijakowski P., Miki S., Miller E.W., Minakata H., Minamino A., Mine S., Mineev O., Mitra A., Miura M., Moharana R., Mollo C.M., Mondal T., Mongelli M., Monrabal F., Moon D.H., Moon C.S., Mora F.J., Moriyama S., Mueller Th.A., Munteanu L., Murase K., Nagao Y., Nakadaira T., Nakagiri K., Nakahata M., Nakai S., Nakajima Y., Nakamura K., Nakamura KI., Nakamura H., Nakano Y., Nakaya T., Nakayama S., Nakayoshi K., Nascimento Machado L., Naseby C.E.R., Navarro-Garcia B., Needham M., Nicholls T., Niewczas K., Nishimura Y., Noah E., Nova F., Nugent J.C., Nunokawa H., Obrebski W., Ochoa-Ricoux J.P., O’Connor E., Ogawa N., Ogitsu T., Ohta K., Okamoto K., O’Keeffe H.M., Okumura K., Onishchuk Y., Orozco-Luna F., Oshlianskyi A., Ospina N., Ostrowski M., O’Sullivan E., O’Sullivan L., Ovsiannikova T., Oyama Y., Ozaki H., Pac M.Y., Paganini P., Palladino V., Paolone V., Pari M., Parsa S., Pasternak J., Pastore C., Pastuszak G., Patel D.A., Pavin M., Payne D., Peña-Garay C., Pidcott C., Pinzon Guerra E., Playfer S., Pointon B.W., Popov A., Popov B., Porwit Kamil, Posiadala-Zezula M., Poutissou J.M., Pozimski J., Pronost G., Prouse N.W., Przewlocki P., Quilain B., Quiroga A.A., Radicioni E., Radics B., Rajda P.J., Renner J., Rescigno M., Retiere F., Ricciardi G., Riccio C., Richards B., Rondio E., Rose H.J., Roskovec B., Roth S., Rott C., Rountree S.D., Rubbia A., Ruggeri A.C., Ruggles C., Russo S., Rychter A., Ryu D., Sakashita K., Samani S., Sánchez F., Sánchez M.L., Sanchez M.C., Sano S., Santos J.D., Santucci G., Sarmah P., Sashima I., Sato K., Scott M., Seiya Y., Sekiguchi T., Sekiya H., Seo J.W., Seo S.H., Sgalaberna D., Shaikhiev A., Shan Z., Shaykina A., Shimizu I., Shin C.D., Shinoki M., Shiozawa M., Sinnis G., Skrobova N., Skwarczynski K., Smy M.B., Sobczyk J., Sobel H.W., Soler F. J. P., Sonoda Y., Spina R., Spisso B., Spradlin B., Stankevich K.L., Stawarz L., Stellacci S.M., Stopa K., Studenikin A.I., Suárez Gómez S.L., Suganuma T., Suvorov S., Suwa Y., Suzuki A.T., Suzuki S.Y., Suzuki Y., Svirida D., Svoboda R., Taani M., Tada M., Takeda A., Takemoto Y., Takenaka A., Taketa A., Takeuchi Y., Takhistov V., Tanaka H., Tanaka H.A., Tanaka H.I., Tanaka M., Tashiro T., Thiesse M., Thompson L.F., Toledo J., Tomatani-Sánchez A.K., Tortone G., Tsui K.M., Tsukamoto T., Tzanov M., Uchida Y., Vagins M.R., Valder S., Valentino V., Vasseur G., Vijayvargi A., Vilela C., Vinning W. G. S., Vivolo D., Vladisavljevic T., Vogelaar R.B., Vyalkov M.M., Wachala T., Walker J., Wark D., Wascko M.O., Wendell R.A., Wilkes R.J., Wilking M.J., Wilson M.R., Wronka S., Xia J., Xie Z., Xin T., Yamaguchi Y., Yamamoto K., Yanagisawa C., Yano T., Yen S., Yershov N., Yeum D.N., Yokoyama M., Yonenaga M., Yoo J., Yu I., Yu M., Zakrzewski T., Zaldivar B., Zalipska J., Zaremba K., Zarnecki G., Ziembicki M., Zietara K., Zito M., Zsoldos S., Core-collapse supernovae are among the most magnificent events in the observable universe. They produce many of the chemical elements necessary for life to exist and their remnants-neutron stars and black holes-are interesting astrophysical objects in their own right. However, despite millennia of observations and almost a century of astrophysical study, the explosion mechanism of core-collapse supernovae is not yet well understood. Hyper-Kamiokande is a next-generation neutrino detector that will be able to observe the neutrino flux from the next galactic core-collapse supernova in unprecedented detail. We focus on the first 500 ms of the neutrino burst, corresponding to the accretion phase, and use a newly-developed, high-precision supernova event generator to simulate Hyper-Kamiokandeʼs response to five different supernova models. We show that Hyper-Kamiokande will be able to distinguish between these models with high accuracy for a supernova at a distance of up to 100 kpc. Once the next galactic supernova happens, this ability will be a powerful tool for guiding simulations toward a precise reproduction of the explosion mechanism observed in nature.

Published
2022

89. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues

Author

Porwit, Anna, primary, Béné, Marie C., additional, Duetz, Carolien, additional, Matarraz, Sergio, additional, Oelschlaegel, Uta, additional, Westers, Theresia M., additional, Wagner‐Ballon, Orianne, additional, Kordasti, Shahram, additional, Valent, Peter, additional, Preijers, Frank, additional, Alhan, Canan, additional, Bellos, Frauke, additional, Bettelheim, Peter, additional, Burbury, Kate, additional, Chapuis, Nicolas, additional, Cremers, Eline, additional, Della Porta, Matteo G., additional, Dunlop, Alan, additional, Eidenschink‐Brodersen, Lisa, additional, Font, Patricia, additional, Fontenay, Michaela, additional, Hobo, Willemijn, additional, Ireland, Robin, additional, Johansson, Ulrika, additional, Loken, Michael R., additional, Ogata, Kiyoyuki, additional, Orfao, Alberto, additional, Psarra, Katherina, additional, Saft, Leonie, additional, Subira, Dolores, additional, te Marvelde, Jeroen, additional, Wells, Denise A., additional, van der Velden, Vincent H. J., additional, Kern, Wolfgang, additional, and van de Loosdrecht, Arjan A., additional

Published
2022
Full Text
View/download PDF

90. Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors

Author

Gerdtsson, Anna Sandström, primary, Matos Rodrigues, Joana de, additional, Eskelund, Christian Winther, additional, Husby, Simon, additional, Grønbæk, Kirsten, additional, Räty, Riikka, additional, Kolstad, Arne, additional, Geisler, Christian, additional, Porwit, Anna, additional, Jerkeman, Mats, additional, and Ek, Sara, additional

Published
2022
Full Text
View/download PDF

91. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues—Recommendations from the European LeukemiaNet

Author

Vincent H. J. van der Velden, Frank Preijers, Ulrika Johansson, Theresia M. Westers, Alan Dunlop, Anna Porwit, Marie C. Béné, Peter Valent, Jeroen te Marvelde, Orianne Wagner‐Ballon, Uta Oelschlaegel, Leonie Saft, Sharham Kordasti, Robin Ireland, Eline Cremers, Canan Alhan, Carolien Duetz, Willemijn Hobo, Nicolas Chapuis, Michaela Fontenay, Peter Bettelheim, Lisa Eidenshink‐Brodersen, Patricia Font, Michael R. Loken, Sergio Matarraz, Kiyoyuki Ogata, Alberto Orfao, Katherina Psarra, Dolores Subirá, Denise A. Wells, Matteo G. Della Porta, Kate Burbury, Frauke Bellos, Elisabeth Weiß, Wolfgang Kern, Arjan van de Loosdrecht, Hematology laboratory, Internal medicine, Hematology, VU University medical center, AII - Cancer immunology, CCA - Cancer biology and immunology, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Radboudumc Nijmegen [The Netherlands], University Hospitals Bristol, Amsterdam UMC - Amsterdam University Medical Center, Royal Marsden Hospital [Surrey, UK], Lund University [Lund], Immunobiology of Human αβ and γδ T Cells and Immunotherapeutic Applications (CRCINA-ÉQUIPE 1), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre hospitalier universitaire de Nantes (CHU Nantes), Medizinische Universität Wien = Medical University of Vienna, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Henri Mondor, University Hospital Carl Gustav Carus [Dresden, Germany], Technische Universität Dresden = Dresden University of Technology (TU Dresden), Karolinska Institutet [Stockholm], King‘s College London, Maastricht University [Maastricht], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Ordensklinikum Linz Elisabethinen, HematoLogics, Inc. [Seattle, WA, USA], Hospital General Universitario 'Gregorio Marañón' [Madrid], Universidad de Salamanca, Instituto de Salud Carlos III [Madrid] (ISC), Metropolitan Research and Treatment Centre for Blood Disorders [Tokyo, Japan] (MRTC Japan), Evangelismos Athens General Hospital, Universidad de Guadalajara, Humanitas University [Milan] (Hunimed), University of Melbourne, Munich Leukemia Laboratory [Munich, Germany], MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), RS: FHML non-thematic output, Immunology, and Bernardo, Elizabeth

Subjects
Histology, MASTOCYTOSIS, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], BONE-MARROW, DIAGNOSTIC-CRITERIA, [SDV.CAN]Life Sciences [q-bio]/Cancer, REFRACTORY CYTOPENIA, CLASSIFICATION, Pathology and Forensic Medicine, pre-analytic issues, 03 medical and health sciences, 0302 clinical medicine, All institutes and research themes of the Radboud University Medical Center, [SDV.CAN] Life Sciences [q-bio]/Cancer, SDG 3 - Good Health and Well-being, hemic and lymphatic diseases, MDS, 030304 developmental biology, 0303 health sciences, flow cytometry, Cell Biology, QUANTIFICATION, LOW-GRADE, 3. Good health, CONSENSUS STATEMENTS, ELN, 030215 immunology, STANDARDS
Abstract

Contains fulltext : 290818.pdf (Publisher’s version ) (Open Access) BACKGROUND: Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. METHODS: Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. RESULTS: We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. CONCLUSIONS: These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice. 01 januari 2023

Published
2023

92. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Author

Loosdrecht, Arjan, Kern, Wolfgang, Porwit, Anna, Valent, Peter, Kordasti, Sharham, Cremers, Eline, Alhan, Canan, Duetz, Carolien, Dunlop, Alan, Hobo, Willemijn, Preijers, Frank, Wagner‐ballon, Orianne, Chapuis, Nicolas, Fontenay, Michaela, Bettelheim, Peter, Eidenschink‐brodersen, Lisa, Font, Patricia, Johansson, Ulrika, Loken, Michael, Marvelde, Jeroen, Matarraz, Sergio, Ogata, Kiyoyuki, Oelschlaegel, Uta, Orfao, Alberto, Psarra, Katherina, Subirá, Dolores, Wells, Denise, Béné, Marie, Della Porta, Matteo, Burbury, Kate, Bellos, Frauke, Velden, Vincent, Westers, Theresia, Saft, Leonie, Ireland, Robin, MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), RS: FHML non-thematic output, Amsterdam UMC - Amsterdam University Medical Center, Munich Leukemia Laboratory [Munich, Germany] (M2L), Lund University [Lund], Medizinische Universität Wien = Medical University of Vienna, King‘s College London, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], The Royal Marsden, Radboud University Medical Center [Nijmegen], Hôpital Henri Mondor, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Ordensklinikum Linz Elisabethinen, HematoLogics, Inc. [Seattle, WA, USA], Hospital General Universitario 'Gregorio Marañón' [Madrid], University Hospitals Bristol, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Universidad de Salamanca, Metropolitan Research and Treatment Centre for Blood Disorders [Tokyo, Japan] (MRTC Japan), University Hospital Carl Gustav Carus [Dresden, Germany], Technische Universität Dresden = Dresden University of Technology (TU Dresden), Evangelismos Athens General Hospital, Universidad de Guadalajara, Immunobiology of Human αβ and γδ T Cells and Immunotherapeutic Applications (CRCINA-ÉQUIPE 1), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre hospitalier universitaire de Nantes (CHU Nantes), Humanitas University [Milan] (Hunimed), Istituto Clinico Humanitas [Milan] (IRCCS Milan), University of Melbourne, Karolinska Institutet [Stockholm], King's College Hospital (KCH), Hematology, CCA - Cancer biology and immunology, Internal medicine, Hematology laboratory, Immunology, and Bernardo, Elizabeth

Subjects
standardization, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], flow cytometry, CONSORTIUM, [SDV.CAN]Life Sciences [q-bio]/Cancer, PROGNOSTIC SCORING SYSTEM, DIAGNOSIS, CYTOGENETICS, myelodysplastic syndromes, CLASSIFICATION, VALIDATION, All institutes and research themes of the Radboud University Medical Center, [SDV.CAN] Life Sciences [q-bio]/Cancer, consensus, hemic and lymphatic diseases, CELLS, SUBGROUPS, ELN, CYTOMORPHOLOGY
Abstract

Contains fulltext : 290800.pdf (Publisher’s version ) (Open Access) This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients. 01 januari 2023

Published
2023

94. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDS‐Flow</scp> Cytometry Working Group

Author

Arjan A. van de Loosdrecht, Wolfgang Kern, Anna Porwit, Peter Valent, Sharham Kordasti, Eline Cremers, Canan Alhan, Carolien Duetz, Alan Dunlop, Willemijn Hobo, Frank Preijers, Orianne Wagner‐Ballon, Nicolas Chapuis, Michaela Fontenay, Peter Bettelheim, Lisa Eidenschink‐Brodersen, Patricia Font, Ulrika Johansson, Michael R. Loken, Jeroen G. te Marvelde, Sergio Matarraz, Kiyoyuki Ogata, Uta Oelschlaegel, Alberto Orfao, Katherina Psarra, Dolores Subirá, Denise A. Wells, Marie C. Béné, Matteo G. Della Porta, Kate Burbury, Frauke Bellos, Vincent H. J. van der Velden, Theresia M. Westers, Leonie Saft, and Robin Ireland

Subjects
Histology, Cell Biology, Pathology and Forensic Medicine
Published
2021

96. Trends in Multiple Health Complaints in Polish Adolescents in Light of Data from 30 European Countries and Canada (2002–2018)

Author

Mazur, Joanna, Klanšček, Helena Jeriček, Augustine, Lilly, Porwit, Katarzyna, Sigmund, Erik, and Šmigelskas, Kastytis

Subjects
trends, Male, Sweden, Original Paper, Schools, Adolescent, subjective complaints, Europe, Adolescent Behavior, Humans, Female, international data, Poland, Child, mental health
Abstract

Background Adolescence is a sensitive period accompanied by rapid developmental changes that can result in health complaints. The aim of the study was to describe the trend of subjective health complaints (HBSC-SCL) of Polish adolescents compared to their peers from 30 other countries and to rank all countries based on a proposed standardised measure. Material and Methods Data from the Health Behaviour in School-Aged Children (HBSC) study collected from 2002 to 2018 were used. The overall number of respondents from 30 countries in the combined sample from five quadrennial rounds was 773,356, including 49.2% boys and 50.8% girls. The HBSC-SCL is a non-clinical measure consisting of eight health complaints, usually analysed in two dimensions of psychological and somatic symptoms. Linear regression analysis was applied to assess the significance of trends of the total index and two subindices in the combined sample and individual countries. Results A significant increasing trend for the eight-item index appeared in Poland only in 13- and 15-year-olds, while only among 15-year-olds in the combined sample from 30 countries. Standardised country rank varied between -1.85 and 2.48 (worst). The countries that achieved extreme negative values (>=1) are France, Hungary, Italy, and Sweden, and the rank for Italy is considerably higher than for other countries. In Poland, the standardised rank for psychological symptoms exceeded the threshold of +1 in 2018. Conclusions The HBSC-SCL index could be useful for monitoring change in adolescent mental health. The proposed method of ranking may allow a broader view of the differences and similarities between countries and help to identify those performing unfavourably against cross-country patterns.

Published
2021

97. The Plasmacytoid Dendritic Cell CD123+ Compartment in Acute Leukemia with or without RUNX1 Mutation: High Inter-Patient Variability Disclosed by Immunophenotypic Unsupervised Analysis and Clustering

Author

Marie C. Béné and Anna Porwit

Subjects
Mutation, Acute leukemia, RUNX1, medicine.diagnostic_test, flow cytometry, Chronic myelomonocytic leukemia, Myeloid leukemia, hemic and immune systems, Plasmacytoid dendritic cell, Biology, acute myeloid leukemia, medicine.disease_cause, medicine.disease, Flow cytometry, unsupervised clustering, chemistry.chemical_compound, chemistry, hemic and lymphatic diseases, medicine, Cancer research, plasmacytoid dendritic cell, Medicine, Interleukin-3 receptor
Abstract

Plasmacytoid dendritic cells (PDC) constitute a small subset of normal bone marrow (BM) cells but have also been shown to be present, sometimes in large numbers, in several hematological malignancies such as acute myeloid leukemia with RUNX1 mutation, chronic myelomonocytic leukemia or, obviously, blastic plasmacytoid dendritic cell neoplasms. These cells have been reported to display somewhat variable immunophenotypic features in different conditions. However, little is known of their plasticity within individual patients. Using an unsupervised clustering tool (FlowSOM) to re-visit flow cytometry results of seven previously analyzed cases of hematological malignancies (6 acute myeloid leukemia and one chronic myelomonocytic leukemia) with a PDC contingent, we report here on the unexpectedly high variability of PDC subsets. Although five of the studied patients harbored a RUNX1 mutation, no consistent feature of PDCs could be disclosed as associated with this variant. Moreover, the one normal single-node small subset of PDC detected in the merged file of six normal BM could be retrieved in the remission BM samples of three successfully treated patients. This study highlights the capacity of unsupervised flow cytometry analysis to delineate cell subsets not detectable with classical supervised tools.

Published
2021

98. Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group

Author

Kern, Wolfgang, primary, Westers, Theresia M., additional, Bellos, Frauke, additional, Bene, Marie Christine, additional, Bettelheim, Peter, additional, Brodersen, Lisa Eidenschink, additional, Burbury, Kate, additional, Chu, Sung‐Chao, additional, Cullen, Matthew, additional, Porta, Matteo Della, additional, Dunlop, Alan Stewart, additional, Johansson, Ulrika, additional, Matarraz, Sergio, additional, Oelschlaegel, Uta, additional, Ogata, Kiyoyuki, additional, Porwit, Anna, additional, Preijers, Frank, additional, Psarra, Katherina, additional, Saft, Leonie, additional, Subirá, Dolores, additional, Weiß, Elisabeth, additional, van der Velden, Vincent H. J., additional, and van de Loosdrecht, Arjan, additional

Published
2022
Full Text
View/download PDF

100. Scintillator ageing of the T2K near detectors from 2010 to 2021

Author

Abe, K., primary, Akhlaq, N., additional, Akutsu, R., additional, Ali, A., additional, Alt, C., additional, Andreopoulos, C., additional, Antonova, M., additional, Aoki, S., additional, Arihara, T., additional, Asada, Y., additional, Ashida, Y., additional, Atkin, E.T., additional, Ban, S., additional, Barbi, M., additional, Barker, G.J., additional, Barr, G., additional, Barrow, D., additional, Batkiewicz-Kwasniak, M., additional, Bench, F., additional, Berardi, V., additional, Berns, L., additional, Bhadra, S., additional, Blanchet, A., additional, Blondel, A., additional, Bolognesi, S., additional, Bonus, T., additional, Bordoni, S., additional, Boyd, S.B., additional, Bravar, A., additional, Bronner, C., additional, Bron, S., additional, Bubak, A., additional, Buizza Avanzini, M., additional, Calabria, N.F., additional, Cao, S., additional, Carter, A.J., additional, Cartwright, S.L., additional, Catanesi, M.G., additional, Cervera, A., additional, Chakrani, J., additional, Cherdack, D., additional, Christodoulou, G., additional, Cicerchia, M., additional, Coleman, J., additional, Collazuol, G., additional, Cook, L., additional, Cudd, A., additional, Davydov, Yu.I., additional, De Roeck, A., additional, De Rosa, G., additional, Dealtry, T., additional, Delogu, C.C., additional, Densham, C., additional, Dergacheva, A., additional, Di Lodovico, F., additional, Dolan, S., additional, Douqa, D., additional, Doyle, T.A., additional, Drapier, O., additional, Duffy, K.E., additional, Dumarchez, J., additional, Dunne, P., additional, Dygnarowicz, K., additional, Eguchi, A., additional, Emery-Schrenk, S., additional, Ershova, A., additional, Fedotov, S., additional, Fernandez, P., additional, Finch, A.J., additional, Fiorentini Aguirre, G.A., additional, Fiorillo, G., additional, Friend, M., additional, Fujii, Y., additional, Fukuda, Y., additional, Fusshoeller, K., additional, Giganti, C., additional, Glagolev, V., additional, Gonin, M., additional, Goodman, E.A.G., additional, Gorin, A., additional, Grassi, M., additional, Guigue, M., additional, Hadley, D.R., additional, Haigh, J.T., additional, Hamacher-Baumann, P., additional, Harris, D.A., additional, Hartz, M., additional, Hasegawa, T., additional, Hassani, S., additional, Hastings, N.C., additional, Hatzikoutelis, A., additional, Hayato, Y., additional, Hiramoto, A., additional, Hogan, M., additional, Holeczek, J., additional, Holin, A., additional, Holvey, T.J., additional, Hong Van, N.T., additional, Honjo, T., additional, Iacob, F., additional, Ichikawa, A.K., additional, Ikeda, M., additional, Ishida, T., additional, Ishitsuka, M., additional, Israel, H.T., additional, Ives, S.J., additional, Iwamoto, K., additional, Izmaylov, A., additional, Izumi, N., additional, Jakkapu, M., additional, Jamieson, B., additional, Jenkins, S.J., additional, Jesús-Valls, C., additional, Jiang, J.J., additional, Jonsson, P., additional, Jung, C.K., additional, Jurj, P.B., additional, Kabirnezhad, M., additional, Kaboth, A.C., additional, Kajita, T., additional, Kakuno, H., additional, Kameda, J., additional, Kasetti, S.P., additional, Kataoka, Y., additional, Katayama, Y., additional, Katori, T., additional, Kawaue, M., additional, Kearns, E., additional, Khabibullin, M., additional, Khotjantsev, A., additional, Kikawa, T., additional, Kikutani, H., additional, King, S., additional, Kisiel, J., additional, Knight, A., additional, Kobata, T., additional, Kobayashi, T., additional, Koch, L., additional, Kogan, G., additional, Konaka, A., additional, Kormos, L.L., additional, Koshio, Y., additional, Kostin, A., additional, Kowalik, K., additional, Kudenko, Y., additional, Kuribayashi, S., additional, Kurjata, R., additional, Kutter, T., additional, Kuze, M., additional, La Commara, M., additional, Labarga, L., additional, Lachner, K., additional, Lagoda, J., additional, Lakshmi, S.M., additional, Lamers James, M., additional, Lamont, I., additional, Lamoureux, M., additional, Last, D., additional, Latham, N., additional, Laveder, M., additional, Lawe, M., additional, Lee, Y., additional, Lin, C., additional, Lindner, T., additional, Lin, S.-K., additional, Litchfield, R.P., additional, Liu, S.L., additional, Longhin, A., additional, Long, K.R., additional, Ludovici, L., additional, Lu, X., additional, Lux, T., additional, Machado, L.N., additional, Magaletti, L., additional, Mahn, K., additional, Malek, M., additional, Mandal, M., additional, Manly, S., additional, Marino, A.D., additional, Marti-Magro, L., additional, Martin, D.G.R., additional, Martini, M., additional, Martin, J.F., additional, Maruyama, T., additional, Matsubara, T., additional, Matveev, V., additional, Mauger, C., additional, Mavrokoridis, K., additional, Mazzucato, E., additional, McCauley, N., additional, McElwee, J., additional, McFarland, K.S., additional, McGrew, C., additional, Mefodiev, A., additional, Megias, G.D., additional, Mellet, L., additional, Metelko, C., additional, Mezzetto, M., additional, Minamino, A., additional, Mineev, O., additional, Mine, S., additional, Miura, M., additional, Molina Bueno, L., additional, Moriyama, S., additional, Mueller, Th.A., additional, Munford, D., additional, Munteanu, L., additional, Nagai, K., additional, Nagai, Y., additional, Nakadaira, T., additional, Nakagiri, K., additional, Nakahata, M., additional, Nakajima, Y., additional, Nakamura, A., additional, Nakamura, H., additional, Nakamura, K., additional, Nakano, Y., additional, Nakayama, S., additional, Nakaya, T., additional, Nakayoshi, K., additional, Naseby, C.E.R., additional, Ngoc, T.V., additional, Nguyen, V.Q., additional, Niewczas, K., additional, Nishimura, Y., additional, Nishizaki, K., additional, Nova, F., additional, Novella, P., additional, Nugent, J.C., additional, O'Keeffe, H.M., additional, O'Sullivan, L., additional, Odagawa, T., additional, Ogawa, T., additional, Okada, R., additional, Okumura, K., additional, Okusawa, T., additional, Owen, R.A., additional, Oyama, Y., additional, Palladino, V., additional, Paolone, V., additional, Pari, M., additional, Parlone, J., additional, Parsa, S., additional, Pasternak, J., additional, Pavin, M., additional, Payne, D., additional, Penn, G.C., additional, Perkin, J.D., additional, Pershey, D., additional, Pickering, L., additional, Pidcott, C., additional, Pintaudi, G., additional, Pistillo, C., additional, Popov, B., additional, Porwit, K., additional, Posiadala-Zezula, M., additional, Prabhu, Y.S., additional, Quilain, B., additional, Radermacher, T., additional, Radicioni, E., additional, Radics, B., additional, Ratoff, P.N., additional, Reh, M., additional, Riccio, C., additional, Rondio, E., additional, Roth, S., additional, Rubbia, A., additional, Ruggeri, A.C., additional, Ruggles, C.A., additional, Rychter, A., additional, Sakashita, K., additional, Sánchez, F., additional, Santucci, G., additional, Schloesser, C.M., additional, Scholberg, K., additional, Scott, M., additional, Seiya, Y., additional, Sekiguchi, T., additional, Sekiya, H., additional, Sgalaberna, D., additional, Shaikhiev, A., additional, Shaykina, A., additional, Shiozawa, M., additional, Shorrock, W., additional, Shvartsman, A., additional, Skwarczynski, K., additional, Smy, M., additional, Sobczyk, J.T., additional, Sobel, H., additional, Soler, F.J.P., additional, Sonoda, Y., additional, Spina, R., additional, Su, H., additional, Suslov, I.A., additional, Suvorov, S., additional, Suzuki, A., additional, Suzuki, S.Y., additional, Suzuki, Y., additional, Sztuc, A.A., additional, Tada, M., additional, Takayasu, S., additional, Takeda, A., additional, Takeuchi, Y., additional, Tanaka, H.K., additional, Tanihara, Y., additional, Tani, M., additional, Tereshchenko, V.V., additional, Teshima, N., additional, Thamm, N., additional, Thompson, L.F., additional, Toki, W., additional, Touramanis, C., additional, Towstego, T., additional, Tsui, K.M., additional, Tsukamoto, T., additional, Tzanov, M., additional, Uchida, Y., additional, Vacheret, A., additional, Vagins, M., additional, Vallari, Z., additional, Vargas, D., additional, Vasseur, G., additional, Vilela, C., additional, Vinning, W.G.S., additional, Vladisavljevic, T., additional, Wachala, T., additional, Waldron, A.V., additional, Walsh, J.G., additional, Wang, Y., additional, Wan, L., additional, Wark, D., additional, Wascko, M.O., additional, Weber, A., additional, Wendell, R., additional, Wilking, M.J., additional, Wilkinson, C., additional, Wilson, J.R., additional, Wood, K., additional, Wret, C., additional, Xia, J., additional, Xu, Y.-h., additional, Yamamoto, K., additional, Yanagisawa, C., additional, Yang, G., additional, Yano, T., additional, Yasutome, K., additional, Yershov, N., additional, Yevarouskaya, U., additional, Yokoyama, M., additional, Yoshimoto, Y., additional, Yu, M., additional, Zaki, R., additional, Zalewska, A., additional, Zalipska, J., additional, Zaremba, K., additional, Zarnecki, G., additional, Zhao, X., additional, Zhu, T., additional, Ziembicki, M., additional, Zimmerman, E.D., additional, Zito, M., additional, and Zsoldos, S., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results